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Abstract 27 
Background: High household peanut consumption is associated with the development of peanut 28 
allergy, especially when peanut allergic cases are compared against atopic controls; thus 29 
environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In 30 
this study we explored the relationship between EPE and peanut sensitization in a population based 31 
cohort.  32 
Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal 33 
peanut ELISA. Peanut sensitization was assessed by peanut specific IgE and peanut protein 34 
allergen molecules (PAM) (Ara h 1, 2 or 3 ≥0.35kU/L). Initial nested case control analysis was 35 
performed (n=411) followed by whole cohort analysis (n=1878). 36 
Results: There was a significant association between EPE around birth and peanut specific IgE at 37 
age 4 years (OR=1.41 95% CI:1.05-1.90, and peanut PAM sensitization at age 8 years (OR=2.11 38 
95% CI:1.38-3.22) compared against controls matched for gender and parental atopy; FLG loss-of-39 
function mutations, egg sensitization at age 4 years, infantile eczema and allergic rhinitis were 40 
significantly associated with peanut sensitization; however, there was no significant interaction with 41 
EPE. When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut 42 
sensitization; however, EPE was associated with peanut PAM sensitization when compared against 43 
egg-sensitized peanut-tolerant controls adjusted odds ratio of 1.56 per unit EPE (95% CI:1.14-2.12).  44 
Conclusions: EPE was associated with an increased risk of peanut specific IgE and peanut PAM 45 
sensitization at 8 years of age when comparing peanut sensitized cases against atopic controls 46 
(egg sensitized children or children matched for parental atopy).  47 
Abstract word count: 251 48 
Key words: BAMSE, egg sensitization, environmental peanut exposure, FLG mutation, infantile 49 
eczema peanut sensitization 50 
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Abbreviations 61 
AIC: Akaike information criterion 62 
Ara h: Arachis hypogaea 63 
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GEE: Generalized Estimating Equations 68 
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QIC: Quasi Likelihood Independence models criterion   72 
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Introduction 73 
Peanut allergy has increased,(1;2) is a leading cause of anaphylaxis in food allergy(3) and has a 74 
significant impact on quality of life for the child and their family.(4;5) Most children react on first known 75 
oral exposure to peanut; thus sensitization must be occurring earlier.
(6;7)
  Understanding the way 76 
children become sensitized to peanut is therefore imperative in order to prevent this condition. 77 
Observational(8) and animal work(9) suggests that epicutaneous peanut exposure and early onset 78 
severe eczema may play an important role in peanut sensitization.  79 
Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, 80 
particularly if the skin barrier is broken through eczema or specific genetic mutations associated with 81 
skin barrier dysfunction (e.g. filaggrin (FLG) mutations or eczema). We have recently shown in the 82 
Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) 83 
cohort that FLG loss-of-function mutations and eczema severity respectively can increase the 84 
impact of early EPE on peanut sensitization and allergy.(10;11).  85 
 86 
A dose response relationship has also been demonstrated between household peanut consumption 87 
(used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing 88 
peanut allergy in young children.(12)  They compared household peanut consumption in peanut 89 
allergic individuals against children who were at high risk of developing peanut allergy (due to the 90 
presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was 91 
ten times higher in households with infants with peanut allergy versus children with egg allergy 92 
without peanut allergy but was only 3 times higher in non atopic controls, highlighting that 93 
household peanut consumption was more likely to be associated with peanut allergy in high risk 94 
children.(12) Peanut antigen in the infant’s bed-dust and play-area-dust is highly positively correlated 95 
with household peanut consumption and stimulates basophils from peanut allergic children, thus 96 
has the potential to also sensitize individuals.(13)  97 
 98 
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Peanut sensitization (specific IgE≥0.35kU/L) is present in up to 10% of children and protein allergen 99 
molecule (PAM) analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown 100 
to improve the specificity and sensitivity of diagnosing peanut allergy.(14;15) In BAMSE, children with 101 
IgE reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in 102 
87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic 103 
symptoms in only 17% of cases which were also milder.(16) Sweden has high levels of birch pollen 104 
sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8;(16;17)  thus, in 105 
this study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) 106 
and pollen cross-reactivity (IgE reactivity to Ara h 8).  107 
This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is 108 
a risk factor for the development of peanut sensitization. The analysis was done in two steps; firstly 109 
among high risk children, in a nested cases analysis and secondly among the whole studied 110 
population (a cohort analysis). Given previous findings we also wanted to ascertain the modifying 111 
effects of FLG loss-of-function mutations, infantile eczema and preceding egg sensitization.  112 
  113 
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Methods 114 
The BAMSE study is an unselected Swedish population birth cohort. The design and methodology 115 
are described elsewhere.(18) In brief 4089 unselected newborn children were recruited from 1994-116 
1996 and have been evaluated for various health conditions over time. No intervention was 117 
performed. The BAMSE study obtained ethical approval for environmental sampling of dust. 118 
Demographics 119 
Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 120 
and 8 years and children were defined as ‘peanut sIgE sensitized’ if peanut specific IgE was 121 
≥0.35kU/L. Peanut allergen molecules (PAM) were assessed at 8 years (ImmunoCAP system, 122 
ThermoFisher, Sweden) and children were considered to be peanut PAM sensitized if Ara h 1, 2 or 123 
3 was ≥0.35kU/L and not peanut PAM sensitized if Ara h 1, 2 and 3 were <0.35kU/L or peanut sIgE 124 
was <0.35kU/L at 8 years (where no peanut PAM available). Children with positive peanut specific 125 
IgE at 8 years of age but with no available PAM analysis were excluded from this analysis. Egg 126 
sensitization was defined as egg specific IgE ≥0.35kU/L at 4 years of age.  127 
Parental atopy was defined as a doctor’s diagnosis of asthma and prescription of asthma 128 
medication and/or a doctor’s diagnosis of hay fever in combination with furred pets- and/or pollen 129 
allergy at the time of questionnaire. 130 
Genotyping was performed for FLG mutations common in Scandinavia by using TaqMan allelic 131 
discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-time-132 
of-flight mass spectrometry for 2282del4. Children with a mutation in any of these positions were 133 
classified as having a loss-of function mutation.  134 
 135 
A reported history of infantile eczema was assessed by questionnaire and was defined as dry skin, 136 
itchy rashes for 2 weeks or more and age specific localization (face or arms/legs extension surfaces 137 
or arms/legs flexures or wrists/ankles flexures) and/or doctor’s diagnosis of eczema during the first 138 
year of life.  139 
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Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed 140 
using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires, 141 
and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8 142 
years respectively.(19) 143 
 144 
Dust collection methodology 145 
Dust samples were collected at a median of 2 months of age from the mother’s mattress. The 146 
mother’s mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control 147 
Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing 148 
filter bags were sealed in plastic bags and stored at -20ºC. Dust samples were sieved and fine dust 149 
was weighed and extracted in proportional volumes of extraction solution as previously 150 
described.(20) Peanut protein in dust was determined using the Veratox polyclonal ELISA against 151 
whole peanut protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) 152 
of the assay was defined as 100ng/ml and samples below this value were defined as 50ng/ml 153 
(LLQ/2).(21) Results were converted from ng/ml into µg peanut protein/gram dust. Due to batch to 154 
batch variability of the Veratox ELISA results were batch corrected prior to being entered into the 155 
final statistical analysis.  156 
 157 
Statistical analysis 158 
Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet 159 
(Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust 160 
(µg/gram) underwent natural log transformation. Initial nested case control analysis was performed 161 
with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a 162 
2:1 control (n=274) to case (n=137) matching. Children with peanut PAM sensitization defined by 163 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were also matched against controls at age 8 years 164 
matched for gender and parental atopy with a 2:1 ratio of controls (n=130) to cases (n=65). 165 
Conditional logistic regression (incorporating matching) was performed for the case control analysis 166 
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using robust standard error for peanut sIgE sensitization at 4 years and peanut PAM sensitization at 167 
age 8 years.  168 
Subsequently analysis was performed for the relationship between early EPE and peanut 169 
sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and 170 
FLG genotyping (n=1878). Logistic regression analysis was performed for peanut PAM sensitization 171 
at 8 years of age. Factors associated with peanut sIgE sensitization were assessed using 172 
Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to 173 
account for repeated measures within individuals at 4 and 8 years. Univariate followed by 174 
multivariate regression analysis was performed including EPE, FLG loss-of-function mutations, 175 
infantile eczema and egg sensitization at 4 years of age plus other covariates significantly 176 
association with peanut sensitization (P≤.05) which also improved the quality of fit of the multivariate 177 
model using the Akaike information criterion (AIC) for logistic regression and the Quasi Likelihood 178 
Independence models criterion (QIC) for GEE analyses.  179 
Where the FLG mutation covariate was entered into the statistical model, participants with missing 180 
ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct FLG 181 
loss-of-function mutations are present in different populations and the FLG loss-of-function 182 
mutations assessed in this study have only been associated with eczema in Caucasian European 183 
populations (22;23) Peanut levels in dust (µg/g) were compared between groups using the Mann-184 
Whitney U test. Proportions between groups (e.g. infantile eczema and FLG mutations) were 185 
compared using Pearson chi-squared. Statistical significance was assessed at P<.05.  186 
  187 
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Results 188 
Details of demographics and clinical characteristics included on this study are described in Table EI.  189 
Median peanut protein [IQR] in dust was 4.07µg/gram [1.58, 11.86]. Peanut extract sIgE 190 
sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Peanut PAM 191 
sensitization at 8 years was 4.1% (n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/l. We 192 
first performed a nested case control analysis, and based on positive findings for this subsequently 193 
proceeded to then analyse the whole BAMSE cohort.  194 
Nested case control analysis for peanut sIgE and PAM sensitization  195 
We compared peanut sensitized children against children without peanut sensitization matched for 196 
gender and parental atopy as described in the statistical methods; EPE was a risk factor for both 197 
peanut extract sIgE sensitization at 4 years and peanut PAM sensitization at 8 years with a 23% 198 
and 29% increased risk of peanut sensitization per natural log (ln) unit increase in EPE respectively 199 
(Table I). In children who were peanut extract sIgE sensitized but not peanut PAM sensitized, there 200 
was only borderline significance towards an association between EPE and peanut sensitization 201 
(OR=1.20, 95% CI: 0.97-1.48).  202 
Differential relationship between EPE and primary peanut PAM sensitization and non-clinically 203 
significant peanut sensitization is displayed in Figure 1. Median peanut protein in dust was higher in 204 
peanut extract sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, n=137) than non-peanut extract 205 
sIgE sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) (P<.01); and higher in peanut PAM 206 
sensitized children (4.64µg/g, IQR 1.58-12.77, n=65) than non-peanut PAM sensitized controls 207 
(2.24µg/g, IQR 0.88-4.74, n=130) (P<.01). 208 
On multivariate conditional logistic regression analysis, EPE was significantly associated with 209 
peanut specific IgE and peanut PAM sensitization with a 1.41- and 2.1-fold increased risk per unit 210 
increase EPE respectively (Table II).  211 
Infantile eczema and egg sensitization were both significantly associated with peanut extract sIgE 212 
and PAM sensitization (Table II). FLG loss-of function mutations increased the risk of peanut 213 
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specific IgE 3.78-fold and peanut PAM sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years 214 
was associated with both peanut specific IgE at age 4 years and peanut PAM sensitization at age 8 215 
years in the multivariate analysis. The number of biological siblings, duration of exclusive and total 216 
breastfeeding and maternal age at baseline were not risk factors for peanut sensitization. There was 217 
no significant interaction between EPE and either infantile eczema, egg sensitization or FLG loss-of-218 
function mutations on peanut PAM sensitization (data not shown).  219 
 220 
Whole cohort analysis for peanut sIgE and PAM sensitization  221 
In a second step following positive findings obtained on case control analysis, analysis was 222 
performed for the relationship between early EPE and peanut sensitization in all children from the 223 
BAMSE cohort with available postnatal maternal bed-dust and FLG genotyping (n=1878). On both 224 
univariate (Table III) and multivariate analysis (Table IV) infantile eczema, egg sensitization, FLG 225 
loss-of function mutation and allergic rhinitis at age 8 years were associated with peanut extract 226 
sIgE at age 4 and 8 years. For PAM sensitization at age 8 significant associations were also seen 227 
on univariate (Table III) and multivariate analysis (Table IV) for infantile eczema, egg sensitization 228 
and allergic rhinitis at age 8 years. However, EPE was no longer associated with peanut 229 
sensitization. There was no interaction between EPE and FLG mutations, infantile eczema, egg 230 
sensitization or parental atopy on peanut sensitization.  231 
 232 
Subgroup analysis of peanut PAM sensitization against egg sensitized non peanut allergic 233 
individuals  234 
On subgroup analysis we compared peanut PAM sensitized children (n=75) against children who 235 
were sensitized to egg (sIgE≥0.35kU/L at age 4 years) but did not go on to develop peanut PAM 236 
sensitization (n=59). EPE was a risk factor for peanut PAM sensitization on both univariate 237 
(OR=1.33 95% CI:1.01-1.74, P<.05, n=134) (Table V) and multivariate analysis (OR=1.56, 95% 238 
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CI:1.14-2.12, P<.01, n=132, AIC: 331) adjusting for allergic rhinitis at age 8 years and infantile 239 
eczema. Peanut levels in household dust were also significantly higher in peanut PAM sensitized 240 
children (median 4.79µg/g, IQR 1.63-12.00) versus egg sensitized, non-peanut PAM sensitized 241 
children (median 2.35µg/g, IQR 1.23-6.15) (P=.03).  242 
We assessed the impact of EPE on peanut sensitization when using other high-risk groups of 243 
children who did not become peanut sensitized (FLG mutations, infantile eczema, parental atopy) 244 
and there was no significant association.   245 
  246 
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Discussion 247 
In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE 248 
(quantified using peanut protein levels from maternal mattress-dust postnatally) and peanut PAM 249 
sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) among high risk children (in a nested cases analysis). 250 
When all children in the whole studied population were assessed, there was no association between 251 
EPE and peanut sensitization; however, on subgroup analysis there was an exposure-response 252 
relationship between EPE and peanut PAM sensitization when compared against high risk egg 253 
sensitized children. 254 
 255 
This supports the findings by Fox et al. where household peanut consumption during the first year of 256 
life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg allergic 257 
controls.(12) The exposure-response relationship between EPE and PS (when compared against 258 
atopic controls) was stronger between EPE and peanut CRD sensitization (Ara h 1,2 or 3≥0.35kU/L) 259 
than between EPE and non-clinically relevant PS (peanut sIgE ≥0.35kU/L but negative results for 260 
Ara h 1,2 or 3<0.35kU/L) (Figure 1). The association between household peanut consumption and 261 
peanut sensitization was also found in a study by Garcia-Boyano et al. (24) and  supports the concept 262 
that EPE increases the risk of clinically relevant peanut sensitization.  263 
 264 
In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin 265 
barrier (infantile eczema and FLG loss-of-function mutations) on peanut sensitization and 266 
allergy.(11;25) Although in BAMSE we did not find significant interactions between EPE and FLG 267 
mutations or infantile eczema on peanut sensitization, we did show on subgroup analysis that early 268 
EPE has more impact in children with certain risk factors for the development of peanut sensitization 269 
(such as parental atopy or egg sensitization) than children without these risk factors. The BAMSE 270 
cohort is relatively non-atopic, being from the general population in Sweden, which may have 271 
contributed to lower strength of associations between EPE and atopic markers.  272 
 273 
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Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this 274 
association has been cited in numerous studies.(8;26) FLG loss-of-function mutations were less 275 
important than infantile eczema in predicting the development of peanut sensitization, and FLG 276 
mutations became more important if infantile eczema was not included in the regression model. 277 
Previous studies have found that children that carry a FLG mutation have an increased risk of 278 
peanut allergy even after adjusting for eczema.(27) In this study eczema seemed to be the overriding 279 
factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in 280 
BAMSE (7.14%) in comparison with other population-based cohorts.(22;27) Egg sensitization was 281 
highly associated with peanut sensitization; which has previously been shown in numerous cohort 282 
studies;(25;28;29) it may be that egg sensitization shows a predisposition to mount allergic antibodies 283 
to other allergens as egg allergy is highly associated with the development of other food allergies, 284 
asthma and aeroallergen sensitization.(30;31) Observational studies have shown that in children with 285 
severe, early onset eczema, up to 50% are sensitized to egg;(26) thus egg sensitization may be a 286 
marker of eczema severity.  287 
Limitations of this study included the lack of diagnostic food challenges to determine peanut allergy; 288 
however, peanut PAM sensitization has been shown to be a much more accurate predictor of 289 
clinically confirmed peanut allergy than peanut specific IgE.(32;33) Caucasian ethnicity was defined as 290 
being born in Sweden as between 1994-1996 (when the BAMSE cohort commenced), most 291 
participants born in Sweden would have been of Northern European descent. In addition participants 292 
from Finland, Greece or Eastern Europe who were not born in Sweden were also defined as 293 
Caucasian.(34) Findings on case control analysis could not be replicated on whole cohort analysis, 294 
therefore these findings need to be confirmed in other population based cohorts. Strength of the 295 
present study includes the population based design and relatively high number of study participants.  296 
 297 
Conclusion 298 
In summary, although EPE did not increase the risk of peanut sensitization in children who did not 299 
already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in 300 
specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later 301 
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peanut sensitization. Further prospective studies are needed to confirm these findings in other 302 
populations.  303 
 304 
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Table EI: Demographics of whole studied BAMSE population with available dust and FLG 407 
genotyping (n=1878) 408 
 
Number of cases 
No. 
data 
points  
Percentage  
Peanut specific IgE ≥ 0.35kU/L at 4 years  103 1572 6.55% 
Peanut specific IgE ≥ 0.35kU/L at 8 years  161 1876 8.58% 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs.  
Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE <0.35kU/L  
(excluding peanut sIgE ≥0.35kU/L with no components) 
75 1854 4.05% 
Avoiding peanut because of previous adverse reaction 73 1878 3.89% 
History of infantile atopic dermatitis 313 1840 17.01% 
At least one FLG mutation (R501X, 2282del or R2447x) 134 1878 7.14% 
Allergic rhinitis (ISAAC definition) (age 4 years) 215 1828 11.76% 
Allergic rhinitis (ISAAC definition) (age 8 years) 288 1865 15.44% 
Egg sIgE≥ 0.35IU/ml at 4 years of age 82 1575 5.21% 
Male gender  973 1871 52.00% 
Caucasian ethnicity 1677 1842 91.04% 
Biological siblings 1695 1870 90.64% 
Parental atopy – (asthma/AR/AD) 838 1858 45.10% 
Maternal age (mean, SD) 30.9 (SD4.49) 1871 N/A 
Peanut protein in maternal bed-dust (µg/g): median [IQR] 4.07 [1.58-11.86] 1878 N/A 
Exclusive breast-feeding duration (months): mean (SD) 5.19 (2.43) 1838 N/A 
Total breast-feeding duration (months): mean (SD) 8.73 (3.31) 1825 N/A 
 409 
  410 
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Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases 411 
versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization 412 
(≥0.35kU/L) at age 4 years and peanut PAM sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) at age 8 413 
years. 414 
  
Peanut sIgE sensitized at age 4 
years (n=411) 
Peanut PAM sensitized at age 8 
years (n=195) 
OR 95% CI P value OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.23 1.06-1.43 <.01 1.29 1.04-1.61 .02 
No. of biological siblings  1.38 0.63-3.03 .42 2.50 0.77-8.16 .13 
≥1 FLG loss-of-function mutation 
(excluding non-caucasians) 
2.67 1.18-6.04 .02 3.00 0.84-10.75 .09 
History of infantile eczema 7.35 4.20-12.83 <.001 6.39 2.95-13.83 <.001 
Egg sIgE sensitization: 4 years 18.91 7.50-47.66 <.001 12.85 3.78-43.67 <.001 
Allergic rhinitis: 4 years (ISAAC) 3.44 1.90-6.23 <.001 2.53 1.04-6.18 .04 
Allergic rhinitis: 8 years (ISAAC) 11.44 5.68-23.07 <.001 12.97 4.54-37.05 <.001 
Exclusively breastfed (months) 0.95 0.88-1.03 .22 0.98 0.87-1.11 .77 
Breastfed (excl/partial) (months) 0.99 0.93-1.05 .74 1.01 0.93-1.11 .76 
Maternal age at baseline (in years) 0.99 0.94-1.04 .65 1.05 0.99-1.12 .12 
  415 
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Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized 416 
cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE 417 
sensitization (≥0.35kU/L) at age 4 years and peanut PAM sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) 418 
at age 8 years. Non-caucasians excluded due to inclusion of FLG mutations as covariate.  419 
  
Peanut sIgE sensitized at age 
4 years (excluding non-
caucasians) (n=237) 
*AIC: 90.78 
Peanut PAM sensitized at age 8 
years (excluding non-
caucasians) (n=143) 
*AIC: 49.19 
OR 95% CI P Value OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.41 1.05-1.90 .02 2.11 1.38-3.22 .001 
≥1 FLG loss-of-function mutation 3.78 0.93-15.36 .06 7.33 1.21-44.21 .03 
History of infantile eczema 2.53 0.98-6.51 .05 3.93 1.03-15.00 .05 
Egg sIgE sensitization: 4 years 28.00 5.24-149.39 <.001 39.9 1.47-1081.68 .03 
Allergic rhinitis: 8 years (ISAAC) 12.57 4.164-37.98 <.001 28.93 3.77-221.61  <.001 
*Smaller AIC is better 420 
  421 
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Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to 422 
account for repeated measures within individuals at 4 and 8 years and logistic regression for peanut 423 
PAM sensitization at age 8 years in the whole BAMSE cohort (n=1878). 424 
  
Univariate GEE for peanut 
sIgE sensitization   
at 4 and 8 years  
Univariate peanut PAM 
sensitization at age 8 years  
OR 95% CI 
P 
Value 
OR 95% CI 
P 
Value 
EPE (µg/gram ln transformed) 0.95 0.86-1.06 .39 1.01 0.86-1.19 .89 
Gender 1.14 0.83-1.56 .43 1.41 0.88-2.26 .15 
Full older siblings  1.08 0.63-1.85 .77 0.86 0.40-1.81 .68 
≥1 FLG loss-of-function mutations 
(excluding non-caucasians) 
1.85 1.08-3.16 .03 1.76 0.82-3.77 .15 
History of infantile eczema 6.49 4.66-9.02 .001 7.94 4.91-12.83 <.001 
Egg sIgE sensitization at 4 years 13.58 8.55-21.58 <.001 11.04 6.13-19.90 <.001 
Allergic rhinitis aged 4 years (ISAAC) 2.82 1.92-4.13 <.001 2.16 1.22-3.83 <.01 
Allergic rhinitis aged 8 years (ISAAC) 8.05 5.78-11.22 <.001 5.87 3.66-9.42 <.001 
Parental atopy  
(asthma and/or hay-fever) 
1.77 1.28-2.44 <.001 1.77 1.10-2.83 .02 
Non-caucasian ethnicity 1.58 0.97-2.57 .07 1.09 0.49-2.43 .79 
Exclusively breastfed in months 0.98 0.94-1.06 .92 0.97 0.88-1.06 .49 
Breastfed (exclusive/partial)  
in months 
0.99 0.94-1.03 .57 0.97 0.91-1.04 .43 
Maternal age at baseline (in years) 1.02 0.98-1.05 .44 1.02 0.97-1.07 .53 
 425 
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Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using 427 
generalised estimating equations (GEE) to account for repeated measures within individuals at 4 428 
and 8 years and logistic regression analysis for peanut PAM sensitization at age 8 years in the 429 
BAMSE cohort. excluding non-caucasians. Goodness of fit assessed by QIC and AIC. 430 
  
Multivariate peanut sIgE 
sensitization (excluding 
non-caucasians) (1388) 
QIC:1094 
Multivariate peanut PAM 
sensitization (excluding 
non-caucasians) (n=1375) 
AIC:767 
OR 95% CI P Value OR 95% CI P Value 
EPE (µg/gram ln transformed)  0.98 0.84-1.13 .75 1.08 0.88-1.32 .48 
≥1 FLG loss-of-function mutations 2.37 1.22-4.60 .01 1.82 0.72-4.57 .20 
History of infantile eczema 3.81 2.44-5.94 <.001 5.51 3.03-10.03 <.001 
Egg sIgE sensitization at 4 years 8.12 4.35-15.15 <.001 6.61 3.16-13.80 <.001 
Allergic rhinitis aged 8 years (ISAAC) 5.57 3.57-8.71 <.001 3.05 1.65-5.63 <.001 
  431 
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Table V: Univariate analysis of factors associated with peanut PAM sensitization (at age 8 years) 432 
versus non peanut PAM sensitization (at age 8 years) in high risk children with preceding egg 433 
sensitization (at age 4 years) (n=134). 434 
  
Peanut PAM sensitization vs. non-peanut sensitized 
egg sensitized controls 
OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.33 1.01-1.74 <0.05 
Gender 1.90 0.95-3.80 0.07 
Full older siblings  0.61 0.17-2.13 0.44 
≥1 FLG loss-of-function mutations  
1.09 0.33-3.56 0.89 
(excluding non caucasians) 
History of infantile eczema 2.51 1.24-5.08 0.01 
Allergic rhinitis aged 4 years (ISAAC) 0.87 0.38-1.96 0.73 
Allergic rhinitis aged 8 years (ISAAC) 2.65 1.26-5.56 0.01 
Parental atopy (asthma and /or hay-fever) 1.34 0.67-2.65 0.41 
Non-caucasian ethnicity 2.55 0.93-6.98 0.07 
Exclusively breastfed in months 0.89 0.77-1.04 0.14 
Breastfed (exclusive/partial) in months 0.99 0.89-1.09 0.76 
Maternal age at baseline (in years) 1.06 0.99-1.14 0.11 
 435 
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Legend 437 
Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut PAM 438 
sensitization (Ara h 1,2 or 3 ≥0.35kU/L) versus children with peanut specific IgE ≥0.35kU/L but with 439 
negative results for peanut PAM (Ara h 1,2 or 3<0.35kU/L). 440 
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Comments for Authors: 
This interesting article in which the authors to investigated whether epicutaneous 
peanut exposure is related to peanut (component) sensitization at year 4 and year 8. 
This work is important and relevant to explore a possible relationship between the 
household peanut consumption and the development of peanut allergy especially as 
it is investigated in an unselected birth cohort.  However, I have concerns about the 
methodology used and therefor about the interpretation and conclusions drawn from 
the results of this article. 
  
Major points: 
-     Was the stepwise data analysis (a nested case control analysis followed by 
whole cohort analysis) chosen for (cost)-efficiency or other reasons? Please explain, 
because if possible and data are available you should prefer to use the whole cohort 
analysis to answer your research questions properly.  
 
The reviewer is correct that the stepwise data analysis (a nested case control 
analysis followed by whole cohort analysis) was chosen for financial and logistical 
reasons. Both the peanut levels in dust and filaggrin analysis had not yet been 
performed thus required the finances and manpower to run these analyses. We 
wanted to see if there was a difference in peanut levels in dust between peanut 
sensitised cases and high risk controls (matched for parental atopy) (n=411) before 
proceeding with the whole cohort (n=1878). We have stated ‘The analysis was done 
in two steps for financial and logistical reasons’ into the last paragraph of the 
introduction (line (track changes manuscript) 130) to highlight this. 
 
-     I think the OR's throughout the article should be interpreted with care here as an 
association was found and no causation. It would be better to speak about an 
increased probability of developing sensitization to peanut with each unit increase of 
EPE instead of a x% risk for peanut sensitization. 
 
We agree with the reviewer that the OR represent association and not causation. We 
have therefore amended the text as suggested throughout the manuscript. 
 
-     Several confounders should be addressed that can influence the association 
found between EPE and peanut sensitization:  the severity of the child's eczema, the 
use of emollients and / or topical steroids, parental atopy (including AD), parental 
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peanut / food allergy, other food allergies in the child (besides egg allergy), oral 
exposure to peanut). 
 
Thank-you for suggesting these potential confounders. We will discuss each in turn 
including their association with peanut sensitization at age 8 years:  
 
1) In BAMSE the severity of the child’s eczema was assessed by the extent of 
localisation reported by the parents in the questionnaire at 1 year of age. The 
extent of localisation of eczema was up to 10 areas (face, scalp, arms/legs, 
armpits, flexures, wrists/ankles, neck, chest/belly or back, front body inside 
nappy, buttocks). The extent of localisation of infantile eczema was 
associated with peanut sensitization on univariate analysis (Table III and V) 
but was no longer significantly associated on multivariate analysis. There was 
no significant interaction between EPE and extent of eczema localisation on 
peanut sensitization. 
 
2) Use of topical steroids was reported by parents within the last year (from age 
1-2 years) at the 2 year questionnaire. Use of topical steroids was associated 
with peanut sensitization on univariate analysis (Table III and V) but was no 
longer significantly associated on multivariate analysis. There was no 
significant interaction between EPE and use of topical steroids on peanut 
sensitization. 
 
3) We included both definitions of parental atopy (with and without eczema) in 
the demographics Table E1, methods section and results section for the 
whole cohort analysis. On univariate logistic regression analysis (Table III), 
the association between parental atopy (excluding eczema) and primary 
peanut sensitization at age 8 years was significant (OR 1.77 (95% CI: 1.1-
2.83) p=0.02), whereas the association between parental atopy (including 
eczema) was not significant (OR 1.50 (95% CI: 0.95-2.39), p=0.09). We 
postulate that adult eczema may be non-atopic and therefore is not related to 
an increased risk of atopy in the child. To demonstrate thus we evaluated the 
rate of eczema within the first year of life in children with parental atopy that 
did or did not include eczema. We found that 24% (143/595) of children with 
parental atopy excluding eczema had infantile eczema whereas only 22.5% 
(185/823) of children with parental atopy including eczema had infantile 
eczema. We therefore used the definition of parental atopy excluding eczema 
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throughout the rest of the manuscript. We have explained this in the methods 
section (line (track changes manuscript) 160-165): 
 
‘This definition of parental atopy was selected rather than the same definition with 
inclusion of a doctor’s diagnosis of eczema (excluding contact dermatitis); this 
was because the children of parents with atopy including eczema were less 
atopic (lower infantile eczema) and parental atopy including eczema was not 
associated with the outcome of interest (primary peanut sensitization at 8 years 
of age); this is probably because adult eczema is often non-atopic.’ 
 
4) The BAMSE study does not have information on parental peanut or food 
allergy or maternal peanut consumption during pregnancy or breastfeeding. 
  
5) The BAMSE study does not have information on oral consumption of peanut 
in the child in the first year of life.  
 
6) The association between other food allergies in the child (besides egg allergy) 
and primary peanut sensitization at age 8 years was assessed using parental 
questionnaires at the 8 year visit where the parents were asked: ‘Is your child 
allergic to any foodstuff?’ An adverse reaction included itching in the mouth, 
nose/eye problems, trouble breathing, vomiting or diarrhoea, eczema or nettle 
rash. Parents were then asked the same questions about specific foods: milk, 
egg, fish, shell-fish, wheat, soy, apple, peach, kiwi, avocado, raw carrot, 
banana, nuts/almond (except peanut). Results are shown in Table III, IV and 
V in the manuscript. Although the majority of the adverse reactions to foods at 
age 8 were associated with peanut sensitization, on multivariate analysis only 
tree nut and soya adverse reactons were significantly associated.  
 
-     To answer the question whether FLG loss-of-function mutations, infantile eczema 
and preceding egg sensitization have modifying effects on the association between 
EPE and peanut sensitization selective samples based on the outcome were drawn 
from the cohort (peanut PAM sensitized versus egg sensitized children). However, to 
conclude whether those proposed factors are effect modifiers, the association 
between EPE and the outcome should be investigated in both strata (with and 
without the possible effect modifier).  For example it should be investigated if there is 
a difference in the association between EPE and peanut sensitization in children with 
eczema compared to children without eczema.  
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The reason we analysed the level of EPE in peanut sensitized versus egg-sensitized, 
peanut-tolerant individuals was because we wanted to mimic the analysis by Fox et 
al (J Allergy Clin Immunol 2009;123:417-23) who compared level of household 
peanut consumption in peanut allergic cases versus egg allergic non-peanut allergic 
infants. In the study by Fox et al. it was shown that household consumption of peanut 
(as a marker of environmental exposure to peanut) was associated with peanut 
allergy especially when compared against egg allergic, non-peanut allergic controls.  
 
We assessed whether there was an interaction between EPE and peanut 
sensitization in children with or without infantile eczema, egg sensitization, FLG 
mutations and parental atopy and there were no significant associations.  
  
Abstract 
-     Line (track changes manuscript) 35 Please explain what kind of statistical 
analysis are performed (dependent / independent variables and which kind of 
modelling) in which subgroup. 
 
We have provided an overview of the dependent (outcome) variable and main 
independent variables (EPE) for the case control, cohort and subgroup analysis and 
have stated which statistical analysis was used (line (track changes manuscript) 36-
43): 
 
‘Initial nested case control analysis was performed comparing peanut sensitized 
cases against high-risk controls (matched for parental atopy) (n=411) using a 
conditional regression analysis. This was followed by whole cohort analysis (n=1878) 
comparing EPE against peanut sIgE sensitization at ages 4 and 8 years using 
Generalized Estimating Equations and against primary peanut sensitization at age 8 
years using a logistic regression model. Finally, a subgroup analysis was performed 
comparing the impact of EPE in peanut sensitized versus egg-sensitized peanut 
tolerant individuals using logistic regression analysis. Levels of EPE were compared 
between groups using the Mann-Whitney U test.’ 
 
-     Line (track changes manuscript) 37  I find this sentence difficult to interpret.  Do 
you mean that a higher level of EPE (in µg/gram? Or the highest quartile compared 
to the lower quartiles?) around birth was significantly associated with the presence of 
peanut sensitization (>0.35kU/L) at year 4? 
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We mean that a higher level of EPE around birth (in µg/gram) is associated with the 
presence of peanut sensitization at age 4 years (we did not compare quartiles). We 
have amended the sentence to make this clearer as follows (line (track changes 
manuscript) 45-48): 
 
‘In the nested case control analysis, a higher level of EPE around birth was 
associated with the presence of peanut specific IgE sensitization at age 4 years 
(OR=1.41, 95% CI:1.05-1.90), and primary peanut sensitization at age 8 years 
(OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. 
 
Introduction 
-     Line (track changes manuscript) 110 What do you mean with a high risk 
population, did you select children with certain risk factors for peanut sensitization for 
this analysis?  
 
We determined these children to be at higher risk of developing peanut allergy as the 
controls were matched to the higher level of parental atopy that was present in the 
primary peanut sensitised cases than in the population overall (46.7% vs. 32.6%). 
This clarification has been added to the methods (line (track changes manuscript) 
207-210). 
 
‘Given that these controls were matched for the higher levels of parental atopy in the 
primary peanut sensitized cases these controls were deemed to be high-risk as the 
primary peanut sensitized cases had higher levels of parental atopy than the 
population overall (46.7% vs. 32.6%).’ 
  
Methods 
-     Did you consider to take a lower limit of sIgE sensitization (especially to peanut 
components) as clinically relevant, e.g. > 0.1 kU? 
 
The results for peanut specific IgE were reported with a cut-off of 0.35kU/l; however, 
Ara h 1,2 and 3 were reported with a lower cut-off of 0.1kU/l. There were 11 data 
points that became positive when we redid the analysis using a cut-off of 0.1kU/L 
instead of 0.35kU/l. We redid the analysis using primary peanut sensitization (Ara h 
1,2 and/or 3) with a cut-off of 0.1kU/l and there was no association between EPE and 
primary peanut sensitization at age 8 years and the other covariate associations did 
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not significantly change therefore we have kept the analysis using a cut-off for Ara h 
1,2 and/or 3 of 0.35kU/l.  
 
-     Line (track changes manuscript) 126 Regarding the non-available PAM analysis 
data: in how many cases occurred missing data?  
 
In line (track changes manuscript) 126 we stated ‘children with positive peanut 
specific IgE at 8 years of age but with no available peanut protein component 
allergen analysis were excluded from this analysis.’ There were 24 children with 
missing data for this analysis because no serum was available to perform this. This 
has now been included in the manuscript of the text (line (track changes manuscript) 
151-153). 
 
‘Twenty-four (1.3%) children with positive peanut specific IgE at 8 years of age but 
with no available serum for peanut protein component allergen analysis were 
excluded from this analysis.’ 
 
- Was there a selection of children in which PAM analysis was performed and 
can this have influenced your results? 
 
All children sensitized to peanut at age 8 years, irrespective of sensitization to birch 
had analysis of Ara h 1,2,3,8 and 9 where enough sample was available. In addition, 
those children who were peanut sensitized at age 4 years but lost their sensitization 
at age 8 were also analysed for these component allergens. All children with negative 
peanut sIgE at age 8 years were assumed to have negative component allergens to 
peanut. We believe this selection is broad enough so as not to have biased our 
results. This information has been added to the manuscript (line (track changes 
manuscript) 142-148).  
 
‘Peanut protein component allergens Ara h 1,2,3,8 and 9 were assessed at 8 years 
(ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to peanut at 
age 8 years, irrespective of sensitization to birch. In addition, those children who 
were peanut sensitized at age 4 years but lost their sensitization at age 8 were also 
analyzed for these allergens. All other children with negative peanut sIgE at age 8 
years were assumed to have negative component allergens to peanut.’ 
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-     Line (track changes manuscript) 128 Why was eczema not taken in to account in 
the parental atopy definition?  
 
We have included both definitions of parental atopy (with and without a history of 
eczema) in the demographics Table E1, methods section and results section for the 
whole cohort analysis. Please see response to previous question by the same 
reviewer. 
 
-     How was the presence of a furred pets- and / or pollen allergy determined?  
 
‘Doctor diagnosed furred pets- and / or pollen allergy’ was self-reported by the 
mother and/or father for the parental atopy definition in the BAMSE questionnaire.  
 
-     Was the GEE modelling only used to select possible predictors of the presence 
of peanut sensitization? And why did you choose for GEE with repeated measures 
and not for one logistic regression model with any sensitization to peanut at age 4 
and/or age 8 as outcome measure?  
 
GEE modelling was used to select possible predictors of the presence of peanut sIgE 
sensitization at age 4 and 8 years using first a univariate then multivariate analysis. 
In the multivariate analysis variables were only included if were significantly 
associated with peanut sensitization (p≤0.05) and if their inclusion also improved the 
quality of fit of the multivariate model using Quasi Likelihood Independence model 
criterion (QIC) or Akaike information criterion (AIC).  
 
We used GEE with repeated measures rather than one logistic regression model with 
any sensitization at peanut at age 4 or age 8 as the outcome measure to account for 
missing data. GEE has built in imputation for missing results using the maximum 
likelihood analysis. This accounts for bias that could be introduced as if the child is 
peanut sensitized at age 4 and data is missing at age 8 they would be presumed to 
be peanut sensitized but if they were not peanut sensitized at age 4 and data was 
missing at age 8 years they would be excluded from the analysis.  
  
 
Results 
-     Table I it would be interesting to split this table according to outcome  
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Table 1 is split according to the outcome at 4 and 8 years. Please advise if you would 
like us to change the structure of the Table.  
 
-     Table II why was allergic rhinitis at year 8 entered in the model instead of year 4 
(as the outcome was assessed at year 4)? 
 
Allergic rhinitis at age 8 years was selected as it improved the fit of the conditional 
logistic regression model (AIC) better than allergic rhinitis at age 4 years. As 
described in the statistical methods ‘In the multivariate analysis variables were only 
included if were significantly associated with peanut sensitization (p≤0.05) on 
univariate analysis and if their inclusion also improved the quality of fit of the 
multivariate model using Quasi Likelihood Independence model criterion (QIC) or 
Akaike information criterion (AIC). This clarification has been added as a footnote to 
Table II. 
 
-     Table E1 Almost 4 % of patients is already avoiding peanut due to a previous 
adverse reaction.  At which point in time was this question asked? 
 
This question was asked at age 8 years; however, we realised that a slightly different 
question was more likey to indicate relevant peanut allergy. Parents were asked ’Is 
your child allergic to any foodstuff?’ which encompassed nose and eye symptoms, 
itch, breathing problems, diahhroea, eczema, rash, ’ then were asked about specific 
foods: ’Any reaction to peanut?’. The question about peanut avoidance did not 
encompass any allergic symptoms.  
 
Also ‘Any reaction to peanut’ and was much more highly associated with primary 
peanut sensitization (OR 157.6 95% CI: 81-305), p<0.0001) than ’avoiding peanut 
because of adverse reaction’ (OR 51.2 95% CI: 29-91, p<0.0001), therefore we used 
the definition ’Any reaction to peanut’ and also used this definition for other food 
allergies.  
 
Do you have more information on the presence of clinical relevant peanut allergy?  
 
Unfortunately no diagnostic oral food challenges were performed as part of the 
BAMSE study as the study was not designed to assess peanut allergy.  
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-     Table E1: parental atopy AD seems included in contrast to the definition 
described in the method section of the article.  
 
We thank the reviewer for pointing out this mistake; this was not meant to state ‘AD’. 
However,  we now include results for parental atopy which include and exclude 
eczema methods and results and Table III. 
 
-     Line (track changes manuscript) 219 Did you also investigate whether there was 
an interaction between EPE and parental atopy and peanut sensitization?  
 
In line (track changes manuscript) 267-269 we stated that in the nested cases 
analysis ‘There was no significant interaction between EPE and either infantile 
eczema, egg sensitization or FLG loss-of-function mutations on primary peanut 
sensitization (data not shown).’   
 
We were not able to assess an interaction between EPE and parental atopy with 
peanut sensitization as the case control analysis was set up by matched for parental 
atopy. 
  
Discussion 
-     In the light of my questions and comments regarding possible confounders and 
effect modifiers between the association of EPE and peanut sensitization, it would be 
necessary to comment on this in the discussion section of the manuscript. 
 
We have included a discussion of the additional variables included in the analysis 
(eczema severity and allergic reactions to a specific food by age 8 years) in the 
discussion (lines (track manuscript) 353-359 and 372-375): 
 
‘Measures of eczema severity (extent of localisation, topical steroid use and 
persistent eczema) were associated with primary peanut sensitization on univariate 
analysis but were no longer associated on multivariate analysis. Eczema severity has 
previous been shown to be an independent risk factor for food sensitization in the 
EAT (Enquiring About Tolerance) study.28 The EAT study used the SCORAD eczema 
severity scoring system; however, this could not be performed in the BAMSE study 
as the evaluations at 1,2,4 and 8 years were based on parental questionnaires. Tree 
nut and/or soya allergy by age 8 was also associated with primary peanut 
sensitization at age 8 years; co-existent peanut and tree-nut allergy has been shown 
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in numerous studies,32, 33 whereas co-existent soya and peanut allergy is reportedly 
low.34’ 
 
We have also included a section in the discussion outlining the variables that we 
could not include which may be possible confounders (line (track changes 
manuscript) 380-386:. 
 
‘Certain potential confounders were not available such as parental peanut allergy or 
other parental food allergies, maternal peanut consumption during pregnancy and 
breast-feeding and infant peanut consumption. Therefore we are unable to assess 
whether infant peanut consumption could have protected the children against 
environmental exposure to peanut as has been shown in previous studies;12, 32 
however, when BAMSE was recruiting participants in 1996 the number of infants 
eating peanut was very low.’ 
 
-     How does the amount of EPE in this birth cohort study correspond to other 
studies? 
 
The median level of peanut protein in maternal bed-dust dust in the BAMSE cohort 
4.07µg/gram [IQR 1.58, 11.86] was similar to that found in another the UK study by 
our group (median 4.19 IQR 0.54-24.89) (Brough et al 2013 JACI; 132(3):623-9).  
 
The level of peanut in dust was higher in a US study (Brough et al. JACI 2015; 
135(1):164-70) that measured peanut from the living room floor (median 39.1ug/g 
IQR 0.4-1.33). It would however be expected that peanut levels would be higher in 
America due to higher levels of peanut consumption. This information has been 
added to the discussion of the manuscript (line (track changes manuscript) 339-344). 
 
-     How do you explain the difference between the association of EPE with extract 
versus component sensitization? 
 
We believe the difference between the association of EPE with extract versus 
component peanut sensitization supports the hypothesis that EPE increases the 
probability of developing clinically relevant peanut sensitization, and therefore that 
these children are more likely to develop peanut allergy. 
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In previous work, Brough et al. (2013 JACI) showed that peanut allergens in dust 
were able to activate basophils of peanut allergic individuals in an allergen specific 
manner. We therefore hypothesise that peanut levels in dust are also able to interact 
with dendritic cells and T cells in the development of clinically relevant peanut allergic 
sensitization. 
 
-     Line (track changes manuscript) 269 How does your data support this 
conclusion? 
 
In line (track changes manuscript) 268-270 we stated: ‘we did show on subgroup 
analysis that early EPE has more impact in children with certain risk factors for the 
development of peanut sensitization (such as parental atopy or egg sensitization) 
than children without these risk factors’. Our data support this conclusion because in 
our nested cases analysis, the association between EPE and peanut sensitization 
was stronger when comparing peanut sensitized cases versus high risk controls 
(matched for parental atopy). In the whole cohort analysis the association between 
EPE and peanut sensitization was stronger when comparing peanut sensitized 
children versus high risk controls (defined by egg sensitization).  
 
We have amended the sentence in the manuscript to better clarify how our data 
supports this conclusion (line (track changes manuscript) 332-335): ‘we did show on 
subgroup analysis that early EPE has more impact on the probability of developing 
peanut sensitization when compared against high risk children (defined by parental 
atopy in the nested cases analysis and egg sensitization in the whole cohort 
analysis) than in children without these risk factors’. However, we also state in the 
discussion that ‘findings on case control analysis could not be replicated on whole 
cohort analysis, therefore these findings need to be confirmed in other population 
based cohorts.’ 
 
Minor points 
-     Throughout the article the abbreviation "protein allergen molecules (PAM)" is 
used while this is no common terminology for component resolved diagnostics or 
sIgE to protein components. 
-     Line (track changes manuscript) 100  "...(PAM) analysis of sIgE to the seed 
storage proteins... 
-     Line (track changes manuscript) 122 "... peanut PAM sensitized if sIgE to..." 
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Thank-you for raising this point. We have removed the term protein allergen molecule 
and PAM and have replaced this by stating sIgE to peanut protein allergen 
components or where we refer to Ara h 1,2 or 3 >0.35kU/l we state ‘primary peanut 
sensitization’.  
 
-     Table E1: the percentage is now confusing why not present a column with 
missing data separately?   
 
We have clarified that the percentage is the ratio of cases compared to the number of 
available data points. If the reviewer wishes we can also include a separate table 
with missing data as E2. 
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Reviewer: 2 
  
Comments for Authors: 
The paper explores an interesting concept- that early transcutaneous sensitization to 
peanut allergen is a risk factor for the development of subsequent peanut allergy. I 
found the paper hard to read with a number of grammatical mistakes and some 
paragraphs were not very clear. Importantly this includes the last two paragraphs of 
the Abstract: this is where the average reader makes the decision whether they will 
read on or move on. 
 
Thank-you for highlighting this. We have made several amendments to the abstract 
following the comments from reviewers and we hope that this now reads more 
clearly. In particular we have simplified the conclusion so that it now reads as follows 
(line (track changes manuscript) 59-63): ‘Higher levels of environmental exposure to 
peanut in the first few months of life appear to increase the probability of developing 
school age peanut sensitization in atopic children (based on egg sensitization and 
parental atopy).’  
 
Much reliance is made that the filaggrin loss of function mutations chosen represent 
the majority of those found in this population but their prevalence appears very low- 
are other mutations perhaps present which means groups have been mis-classified? 
  
The prevalence of FLG loss-of-function mutations is low as this is an unselected 
population based birth cohort rather than a high-risk eczema cohort. In European 
populations the two most prevalent mutations in the FLG gene are 2282del4 and the 
R501X; this has been widely replicated in many studies. Three FLG mutations 
analysed (2282del4, R501X and R2447X) had frequencies of 4%, 2% and 1% 
respectively in the BAMSE study which are similar to the frequencies found in a 
German cross-sectional material (Weidinger et al JACI Vol 121, No 5, 1203-1209, 
2008). The mutation next in frequency (0.2%) is S3247X. It is reasonable to assume 
that the frequency for this mutation would be at a similar level in the German and 
Swedish cohorts. S3247X carriers in the BAMSE cohort would therefore have 
amounted to approximately 4 individuals. Therefore, we do not think that the 
additional information from these few individuals would change any of the 
conclusions in our study.  
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It would have been valuable to have measured transepidermal water loss in all 
infants or particularly the high atopy group.  
 
We agree with the reviewer that measurement of transepidermal water loss during 
infancy would have been a valuable measure of skin barrier function; however, the 
BAMSE cohort children were recruited in 1996 and at this time the body of evidence 
linking TEWL to eczema was not yet available.  
 
The study suffers from its design- the reviewer suspects the original hypothesis 
behind BAMSE did not include measurement of peanut allergen nor the early 
development of eczema.  
 
The reviewer is correct in stating that the original study design for BAMSE did not 
include measurement of peanut allergen as peanut allergy was very rare in Sweden 
in 1996. The early development of eczema was; however, one of the original 
analyses for the BAMSE study. 
 
It would surely have been preferable to measure peanut allergen in the infant's cot 
where they spend most of their early life rather than their mother's bed?  
 
Unfortunately dust was not sampled from the infant’s cot in the BAMSE study. The 
rationale for this was that most of the infants recruited to the study were first-borns 
thus the mattress would have been new. We have, however, shown in a previous 
publication that there is a high correlation between levels of peanut protein in the bed 
of the mother and infant-cot (correlation coefficient 0.844 (95% CI: 0.708-0.919), 
p<0.001) during the first year of life. (Brough et al. Distribution of peanut protein in 
the home environment. J Allergy Clin Immunol 2013;132:623-9). 
 
Definition of eczema based on questionnaire is prone to major errors as has been 
seen in other epidemiological studies- to reach firm conclusions infants must be 
regularly examined prospectively.  
 
The eczema questionnaires used at age 1 and 2 years in the BAMSE study were 
previously validated in the publication by Bohme M et al. (Atopic Dermatitis and 
Concomitant Disease Patterns in children up to two year of age. 2002;82:98-103). 
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Fifty consecutive children aged 0-4 years of age were seen in clinic and their parents 
were asked to fill in this questionnaire before meeting the doctor. The questionnaire 
contained, among other questions, the questions diagnostic for eczema from the 
main study questionnaires. The children were then examined by a Dermatologist to 
determine whether they had eczema according to the criteria from Hanifin JM and 
Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; Suppl 
92:44-47. The sensitivity of the questionnaire assessment compared with the clinical 
diagnosis by the dermatologist was 92% and the specificity was 100%.This 
information has been included in the manuscript (line 171-172) and the reference 
from Bohme et al has also been included (ref 20).  
 
There is as a result little information of eczema SEVERITY in infancy- which must 
surely be relevant to degree of sensitization if this hypothesis is correct (peanut 
sensitization occurs first through the skin). 
 
Eczema severity (defined by extent of localisation of eczema, use of topical steroids 
and persistent eczema at age 8 years) was positively associated with peanut 
sensitization on univariate analysis, but was no longer significant on multivariate 
analysis. This is in contrast to other studies that have shown that eczema severity is 
an independent risk factor for sensitization; however these studies used SCORAD 
assessments which were not available in BAMSE. 
 
We are not told of maternal allergic status- could it be allergen levels were lower in 
some homes because of maternal peanut allergy? Do we know of maternal peanut 
intake in pregnancy and perhaps more importantly whilst breast-feeding [I 
understand the majority of Swedish mothers choose to breast feed-] did those with 
atopic personal or infant history do so for longer?  
 
The BAMSE cohort does not unfortunately have information on parental peanut 
allergy, parental food allergy or maternal peanut consumption during pregnancy or 
breastfeeding as it was not originally designed to assess peanut allergic outcomes. 
There is evidence that mothers breastfed marginally longer in BAMSE if there was 
one atopic parent vs no atopy (exclusive breastfeeding 79.3% if no parental atopy vs 
80.8% if one parent atopic); if both parents were atopic this increased to 85.8% (Kull 
et al JACI 2004; 114:755-60 (Table 1)). Duration of breastfeeding (both exclusive and 
partial) has been included as a covariate in the analysis (Table I and III). 
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It is hardly surprising infants with eczema have a higher rate of sensitization- this has 
been repeatedly demonstrated but it has also been demonstrated such sensitization 
commonly does NOT translate into clinical allergy, something the authors have not 
sought to demonstrate. It has recently been demonstrated in an ingenious paper 
(Fukuie T et al ( J Dermatol. 2016 Nov;43(11):1283-1292) that measures of 
sensitization improve as better eczema control is achieved. As the authors of this 
present study are aware, sensitization does NOT translate into allergy. The authors 
rely on high levels of specific IgE to components of peanut and argue this reflects a 
higher likelihood these children are also peanut allergic but a very recent paper has 
cast serious doubt on the reliability of levels of  component-based [protein allergen 
molecules] specific IgE to predict severe allergy[van Veen et al. BMC Pediatrics 
(2016) 16:74].  
 
We agree that the presence of IgE directed against peanut protein component 
allergens does not always translate into allergy; however, the premise of this study 
was to assess whether environmental peanut exposure is associated with peanut 
sensitization as the first step towards allergy. We would have liked to assess whether 
EPE was associated with OFC proven peanut allergy; however, this information was 
not available in BAMSE as the study was not designed to assess peanut allergic 
outcomes. 
 
The study by van Veen et al. (BMC Pediatrics; 2016: 16:74) assesses the diagnostic 
performance of peanut SPT, peanut sIgE to whole extract and peanut sIgE to 
component allergens (Ara h 1,2 and 3) against oral food challenges to peanut. They 
found that peanut SPT and peanut sIgE against component allergens were 
significantly associated with a positive outcome on peanut oral food challenge 
(p<0.0001); however, they were not associated with the severity of reaction or 
eliciting dose on food challenge.  
 
In this manuscript we did not assume that primary peanut sensitization (Ara h 1,2 or 
3 >0.35kU/l) was linked to severe peanut allergy; only that it was more likely to 
predict clinical peanut allergy (regardless of the level of severity).  
 
I am surprised the authors report allergic rhinitis at 8 years in these groups (which 
appears at least at first sight to have little to do with peanut sensitization or allergy 
but may have minor interest in understanding false-positive specific IgE to Ara-8) but 
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do not report how many children still suffer from eczema- a surrogate marker of their 
early eczema severity.  
 
We did indeed include allergic rhinitis at 8 years as a marker for false positive IgE 
directed against Ara h 8. We have now included this information as a footnote of 
Table1. Eczema at age 8 years (OR 2.85, 95% CI: 1.69-4.81, p<0.0001) was 
associated with peanut sensitization at age 8 years on univariate analysis but was no 
longer associated on multivariate analysis. 
 
The authors should discuss why cutaneous peanut exposure in British and Swedish 
children with early onset eczema is apparently associated with later peanut 
sensitization (and purportedly peanut allergy) whereas high levels of exposure in the 
same circumstances in Israel (where early infantile eczema  is also very common 
and where peanut consumption is actually higher than either of those european 
countries) does not.  
 
In Israel, infants are weaned onto a peanut containing food from 4 months of age 
which we believe is the reason why children in Israel do not have high levels of 
peanut allergy despite high household peanut consumption. This observation was 
published by (Du Toit G JACI 2010) and was the basis of the intervention for the 
LEAP study. The protective effect of infant peanut consumption against 
environmental peanut exposure was also shown in the paper by Fox et al. (J Allergy 
Clin Immunol 2009;123:417-23) where household peanut consumption during infancy 
increased the risk of developing peanut allergy, but not in children already consuming 
peanut during the first year of life. The Dual Allergen Exposure Hypothesis (Lack G 
JACI 2010) describes this balance of exposures during the first year of life where 
depending on whether the exposure to peanut is through the skin or gut, the immune 
system is then primed to develop allergy versus tolerance respectively.  
 
We unfortunately do not have information on peanut consumption during infancy in 
the BAMSE study, thus we are unable to show the protective effect of oral 
consumption on preventing the development of peanut allergy. However peanut 
consumption in 1996 in Sweden was low. We have added the following text into the 
discussion (line (track changes manuscript) 380-386): 
 
‘Certain potential confounders were not available as the BAMSE study was not 
originally designed to evaluate risk factors for peanut allergy, such as parental 
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peanut or other food allergy, maternal peanut consumption during pregnancy and 
breast-feeding and infant peanut consumption. Therefore we are unable to assess 
whether infant peanut consumption could have protected the children against peanut 
sensitization as has been shown in previous studies (Fox et al. J Allergy Clin 
Immunol 2009;123:417-23, Du Toit G et al. J Allergy Clin Immunol. 2008 
Nov;122(5):984-91); however, when BAMSE was recruiting participants in 1996 the 
number of infants eating peanut was very low.’ 
 
It is also disappointing studies where at risk infants are prospectively treated with 
emollient (to reduce skin exposure to allergens) have shown whilst eczema severity 
is reduced, allergic sensitization is not. 
 
We agree that the study by Horimukai K et al. JACI 2014 did not show a reduction in 
sensitization to egg despite a 32% reduction in eczema; however, the IgE 
measurements for egg used in this study were not standard immunoCAPS therefore 
we are unsure as to validity of these measures. In addition, this was a small study 
thus with larger numbers an effect may be seen given that there was a higher egg 
sensitization rate in those children who developed eczema versus in children who did 
not develop eczema (odds ratio, 2.86; 95% CI, 1.22-6.73). We await the results of the 
Barrier Enhancement and Eczema Prevention (BEEP) study which will be assessing 
peanut sensitization after emollient application during infancy. 
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Word count: 3528 25 
Short Title: Environmental peanut exposure and peanut sensitization in BAMSE  26 
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Abstract 27 
Background: High household peanut consumption is associated with the development of peanut 28 
allergy, especially when peanut allergic cases are compared against atopic controls; thus 29 
environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In 30 
this study we explored the relationship between EPE and school-age peanut sensitization in a 31 
population based cohort.  32 
Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal 33 
peanut ELISA. Peanut sensitization was assessed by specific IgE to peanut extract and sIgE to 34 
peanut protein component allergens Ara h 1, 2 or 3 ≥0.35kU/L (primary peanut sensitization). Initial 35 
nested case control analysis was performed comparing peanut sensitized cases against high-risk 36 
controls (matched for parental atopy) (n=411) using a conditional regression analysis. This was 37 
followed by whole cohort analysis (n=1878) comparing EPE against peanut sIgE sensitization at 38 
ages 4 and 8 years using Generalized Estimating Equations and against primary peanut  39 
sensitization at age 8 years using a logistic regression model. Finally, a subgroup analysis was 40 
performed comparing the impact of EPE in peanut sensitized versus egg-sensitized, peanut tolerant 41 
individuals using logistic regression analysis. Levels of EPE were compared between groups using 42 
the Mann-Whitney U test. 43 
Results: In the nested case control analysis, a higher level of EPE around birth was associated with 44 
peanut specific IgE sensitization at age 4 years (OR=1.41, 95% CI:1.05-1.90), and primary peanut 45 
sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. 46 
When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut 47 
sensitization; however, on subgroup analysis EPE was associated with primary peanut sensitization 48 
when compared against egg-sensitized peanut-tolerant controls with an adjusted odds ratio of 1.44 49 
per unit EPE (95% CI:1.06-1.94). There was no significant interaction between EPE and FLG loss-50 
of-function mutations, egg sensitization at age 4 years, infantile eczema or parental atopy on peanut 51 
sensitization. 52 
 53 
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Conclusions: Higher levels of environmental exposure to peanut in the first few months of life 54 
appear to increase the probability of developing school age peanut sensitization in atopic children 55 
(based on egg sensitization and parental atopy). 56 
 Abstract word count: 343  57 
Key words: BAMSE, egg sensitization, environmental peanut exposure, FLG mutation, infantile 58 
eczema peanut sensitization 59 
  60 
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AIC: Akaike information criterion 71 
Ara h: Arachis hypogaea 72 
BAMSE: Children/’Barn’ Allergy Milieu Stockholm Epidemiological project  73 
CI: confidence intervals 74 
EPE: environmental peanut exposure  75 
FLG: gene encoding the protein filaggrin 76 
GEE: Generalized Estimating Equations 77 
ISAAC: International Study of Asthma and Allergies in Childhood 78 
IQR: Interquartile range 79 
QIC: Quasi Likelihood Independence models criterion   80 
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Introduction 81 
Peanut allergy has increased,1, 2 is a leading cause of anaphylaxis in food allergy3 and has a 82 
significant impact on quality of life for the child and their family.4, 5 Most children react on first known 83 
oral exposure to peanut; thus sensitization must be occurring earlier.
6, 7
  Understanding the way 84 
children become sensitized to peanut is therefore imperative in order to prevent this condition. 85 
Observational8 and animal work9, 10 suggests that epicutaneous peanut exposure and early onset 86 
severe eczema may play an important role in peanut sensitization. Epicutaneous exposure may be 87 
the route that peanut levels in dust sensitize a child in early life, particularly if the skin barrier is 88 
broken through eczema or specific genetic mutations associated with skin barrier dysfunction (e.g. 89 
filaggrin (FLG) mutations or eczema). We have recently shown in the Manchester Asthma and 90 
Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) cohort that FLG loss-of-91 
function mutations and eczema severity respectively can increase the impact of early EPE on 92 
peanut sensitization and allergy.11, 12  93 
 94 
A dose response relationship has also been demonstrated between household peanut consumption 95 
(used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing 96 
peanut allergy in young children.13 Fox et al. compared household peanut consumption in peanut 97 
allergic individuals against children who were at high risk of developing peanut allergy (due to the 98 
presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was 99 
ten times higher in households with infants with peanut allergy versus children with egg allergy 100 
without peanut allergy but was only 3 times higher in non atopic controls, highlighting that household 101 
peanut consumption was more likely to be associated with peanut allergy in high risk children.13 102 
Household peanut consumption and peanut sensitization has also been associated in other 103 
studies.14 Peanut antigen in the infant’s bed-dust and play-area-dust is highly positively correlated 104 
with household peanut consumption and stimulates basophils from peanut allergic children, thus 105 
has the potential to also sensitize individuals.15  106 
 107 
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Peanut sensitization (specific IgE≥0.35kU/L) is present in up to 10% of children and protein allergen 108 
molecule analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown to 109 
improve the specificity and sensitivity of diagnosing peanut allergy.16, 17 In BAMSE, children with IgE 110 
reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in 111 
87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic 112 
symptoms in only 17% of cases which were also milder.18 Sweden has high levels of birch pollen 113 
sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8;18-20  thus, in this 114 
study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) and 115 
pollen cross-reactivity (IgE reactivity to Ara h 8).  116 
 117 
This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is 118 
a risk factor for the development of school-age peanut sensitization. The analysis was done in two 119 
steps for financial and logistical reasons; firstly among high risk children (with parental atopy 120 
matched to peanut sensitised cases), in a nested cases analysis and secondly among the whole 121 
studied population (a cohort analysis). Given previous findings we also wanted to ascertain the 122 
modifying effects of FLG loss-of-function mutations, infantile eczema and preceding egg 123 
sensitization.  124 
  125 
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Methods 126 
The BAMSE study is an unselected Swedish population birth cohort. The design and methodology 127 
are described elsewhere.21 In brief 4089 unselected newborn children were recruited from 1994-128 
1996 and have been evaluated for various health conditions over time. No intervention was 129 
performed. The BAMSE study obtained ethical approval for environmental sampling of dust. 130 
Demographics 131 
Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 132 
and 8 years and children were defined as ‘peanut sIgE sensitized’ if peanut specific IgE was 133 
≥0.35kU/L. Peanut protein component allergens Ara h 1,2,3,8 and 9 were assessed at 8 years 134 
(ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to peanut at age 8 years, 135 
irrespective of sensitization to birch. In addition, those children who were peanut sensitized at age 4 136 
years but lost their sensitization at age 8 were also analyzed for these allergens. All other children 137 
with negative peanut sIgE at age 8 years were assumed to have negative component allergens to 138 
peanut. Children were considered to have primary peanut sensitization if Ara h 1, 2 or 3 was 139 
≥0.35kU/L and no primary peanut sensitization if Ara h 1, 2 and 3 were <0.35kU/L or peanut sIgE 140 
was <0.35kU/L at 8 years (where no sIgE peanut protein component allergens were available). 141 
Twenty-four (1.3%) children with positive peanut specific IgE at 8 years of age but with no available 142 
serum for peanut protein component allergen analysis were excluded from this analysis. Egg 143 
sensitization was defined as egg specific IgE ≥0.35kU/L at 4 years of age. Previous allergic  144 
reactions to a food including itching in the mouth, nose/eye problems, trouble breathing, vomiting or 145 
diarrhoea, eczema or nettle rash was used from parental questionnaires at age  8 years. 146 
 147 
Parental atopy was defined as a doctor’s diagnosis of asthma and prescription of asthma 148 
medication and/or a doctor’s diagnosis of hay fever in combination with furred pets- and/or pollen 149 
allergy at the time of questionnaire. This definition of parental atopy was selected rather than the 150 
same definition with inclusion of a doctor’s diagnosis of eczema (excluding contact dermatitis); this 151 
was because the children of parents with atopy including eczema were less atopic (lower infantile 152 
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eczema) and parental atopy including eczema was not associated with the outcome of interest 153 
(primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-154 
atopic. Genotyping was performed for FLG mutations common in Scandinavia by using TaqMan 155 
allelic discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-156 
time-of-flight mass spectrometry for 2282del4. Children with a FLG mutation in any of these 157 
positions were classified as having a FLG loss-of function mutation. 158 
 159 
A reported history of infantile eczema was assessed by a validated eczema questionnaire with 160 
sensitivity of 92% and specificity of 100%.22 Eczema was defined as dry skin, itchy rashes for 2 161 
weeks or more and age specific localization (face or arms/legs extension surfaces or arms/legs 162 
flexures or wrists/ankles flexures) and/or doctor’s diagnosis of eczema after 3 months and up to 1 163 
year of age. Severity of eczema was assessed from questionnaires using three different measures:  164 
1) Extent of localization of eczema (up to 10 areas) at or before their one year assessment  165 
2) Topical steroids used as treatment for an itchy rash in the last year at their two year assessment 166 
(not available at their one year assessment) 167 
3) Persistent eczema at age 8 years (using the same definition as above). 168 
 169 
Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed 170 
using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires, 171 
and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8 172 
years respectively.23 173 
 174 
Dust collection methodology 175 
Dust samples were collected at a median of 2 months of age from the mother’s mattress. The 176 
mother’s mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control 177 
Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing 178 
filter bags were sealed in plastic bags and stored at -20ºC. Dust samples were sieved and fine dust 179 
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was weighed and extracted in proportional volumes of extraction solution as previously described.24 180 
Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut 181 
protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) of the assay 182 
was defined as 100ng/ml and samples below this value were defined as 50ng/ml (LLQ/2).25 Results 183 
were converted from ng/ml into µg peanut protein/gram dust. Due to batch to batch variability of the 184 
Veratox ELISA results were batch corrected prior to being entered into the final statistical analysis.  185 
 186 
Statistical analysis 187 
Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet 188 
(Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust 189 
(µg/gram) underwent natural log transformation. Initial nested case control analysis was performed 190 
with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a 191 
2:1 control (n=274) to case (n=137) matching. Children with primary peanut sensitization defined by 192 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were matched against controls at age 8 years with the 193 
same sex and level of parental atopy with a 2:1 ratio of controls (n=130) to cases (n=65). Given that 194 
these controls were matched for the higher levels of parental atopy in the primary peanut sensitized 195 
cases these controls were deemed to be high-risk as the primary peanut sensitized cases had 196 
higher levels of parental atopy than the population overall (46.7% vs. 32.6%). Conditional logistic 197 
regression (incorporating matching) was performed for the case control analysis using robust 198 
standard error for peanut sIgE sensitization at 4 years and primary peanut sensitization at age 8 199 
years.  200 
 201 
Subsequently analysis was performed for the relationship between early EPE and peanut 202 
sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and 203 
FLG genotyping (n=1878). Logistic regression analysis was performed for primary peanut 204 
sensitization at 8 years of age. Factors associated with peanut sIgE sensitization were assessed 205 
using Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to 206 
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account for repeated measures within individuals at 4 and 8 years. Univariate followed by 207 
multivariate regression analysis was performed including EPE plus other covariates significantly 208 
associated with peanut sensitization (P≤.05) which also improved the quality of fit of the multivariate 209 
model using the Akaike information criterion (AIC) for logistic regression and the Quasi Likelihood 210 
Independence models criterion (QIC) for GEE analyses.  211 
 212 
Where the FLG mutation covariate was entered into the statistical model, participants with missing 213 
ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct FLG 214 
loss-of-function mutations are present in different populations and the FLG loss-of-function 215 
mutations assessed in this study have only been associated with eczema in Caucasian European 216 
populations 26, 27 Peanut levels in dust (µg/g) were compared between groups using the Mann-217 
Whitney U test. Statistical significance was assessed at P<.05.  218 
  219 
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Results 220 
Details of demographics and clinical characteristics included on this study are described in Table EI.  221 
Median peanut protein [IQR] in dust was 4.07µg/gram [1.58, 11.86]. Peanut extract sIgE 222 
sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Primary peanut 223 
sensitization at 8 years was 4.1% (n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/l. We first 224 
performed a nested case control analysis, and based on positive findings for this subsequently 225 
proceeded to then analyse the whole BAMSE cohort.  226 
 227 
Nested case control analysis for peanut sIgE and primary peanut sensitization  228 
We compared peanut sensitized children against children without peanut sensitization matched for 229 
gender and parental atopy as described in the statistical methods; EPE was a risk factor for both 230 
peanut extract sIgE sensitization at 4 years and primary peanut sensitization at 8 years with a 23% 231 
and 29% increased probability of developing peanut sensitization per natural log (ln) unit increase in 232 
EPE respectively (Table I). In children who were peanut extract sIgE sensitized but not sensitized to 233 
peanut protein component allergens Ara h 1, 2 and/or 3, there was only borderline significance 234 
towards an association between EPE and peanut sensitization (OR=1.20, 95% CI: 0.97-1.48).  235 
 236 
Differential relationship between EPE and primary peanut sensitization and non-clinically significant 237 
peanut sensitization is displayed in Figure 1. Median peanut protein in dust was higher in peanut 238 
extract sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, n=137) than non-peanut extract sIgE 239 
sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) (P<.01); and higher in primary peanut  240 
sensitized children (4.64µg/g, IQR 1.58-12.77, n=65) than in control children that were not 241 
sensitized to Ara h 1,2 or 3 (2.24µg/g, IQR 0.88-4.74, n=130) (P<.01). 242 
 243 
On multivariate conditional logistic regression analysis, EPE was significantly associated with 244 
peanut specific IgE and primary peanut sensitization with a 1.41- and 2.1-fold increased probability 245 
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of developing peanut sensitization per unit increase EPE respectively (Table II). Infantile eczema 246 
and egg sensitization were both significantly associated with sensitization to peanut extract and 247 
sensitization to peanut protein component allergens Ara h 1, 2 and/or 3.(Table II). FLG loss-of 248 
function mutations increased the probability of developing peanut specific IgE sensitization 3.78-fold 249 
and primary peanut sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated with 250 
both the probability of developing peanut specific IgE sensitization at age 4 years and primary 251 
peanut sensitization at age 8 years in the multivariate analysis. The number of biological siblings, 252 
duration of exclusive and total breastfeeding and maternal age at baseline were not associated with 253 
peanut sensitization. There was no significant interaction between EPE and either infantile eczema, 254 
egg sensitization or FLG loss-of-function mutations on primary peanut sensitization (data not 255 
shown).  256 
 257 
Whole cohort analysis for peanut extract sIgE sensitization and primary peanut sensitization 258 
In a second step following positive findings obtained on case control analysis, we assessed the 259 
relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with 260 
available postnatal maternal bed-dust and FLG genotyping (n=1878). On both univariate (Table III) 261 
and multivariate analysis (Table IV) infantile eczema, egg sensitization at age 4 years, tree nut and 262 
soya allergy at age 8 years, FLG loss-of function mutation and allergic rhinitis at age 8 years were 263 
associated with the probability of peanut sIgE sensitization at age 4 and 8 years. For primary peanut 264 
sensitization at age 8 significant associations were also seen on univariate (Table III) and 265 
multivariate analysis (Table IV) for infantile eczema, egg sensitization, tree nut and soya allergy at 266 
age 8 years and allergic rhinitis at age 8 years. Although measures of eczema severity and several 267 
other food allergies at age 8 years were significantly association with peanut sensitization on 268 
univariate analysis, these variables were no longer significantly associated on multivariate analysis. 269 
EPE was not associated with peanut sIgE sensitization or primary peanut sensitization. There was 270 
no interaction between EPE and FLG mutations, infantile eczema, egg sensitization, allergic  271 
reaction to tree nut or soya by age 8 years, or parental atopy on peanut sensitization.  272 
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 273 
Subgroup analysis of primary peanut sensitization against egg sensitized non peanut 274 
allergic individuals  275 
On subgroup analysis we compared primary peanut sensitized children (n=75) against children who 276 
were sensitized to egg (sIgE≥0.35kU/L at age 4 years) but did not go on to have primary peanut 277 
sensitization at age 8 years (n=59). EPE increased the probability of primary peanut sensitization on 278 
both univariate (OR=1.33 95% CI:1.01-1.74, P<.05, n=134) (Table V) and multivariate analysis 279 
(OR=1.44, 95% CI:1.06-1.94, P0.018, n=133, AIC: 167) adjusting for infantile eczema and allergic  280 
reaction to soya by age 8 years. Peanut levels in household dust were also significantly higher in 281 
primary peanut sensitized children (median 4.79µg/g, IQR 1.63-12.00) versus egg sensitized, non-282 
primary peanut sensitized children (median 2.35µg/g, IQR 1.23-6.15) (P=.03). We assessed the 283 
impact of EPE on peanut sensitization when using other high-risk groups of children who were not 284 
peanut sensitized at age 8 years (FLG mutations, infantile eczema, soya allergy and parental atopy) 285 
and there was no significant association.   286 
  287 
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Discussion 288 
In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE 289 
(quantified using peanut protein levels from maternal mattress-dust postnatally) and primary peanut 290 
sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) among high risk children (in a nested cases analysis). 291 
When all children in the whole studied population were assessed, there was no association between 292 
EPE and peanut sensitization; however, on subgroup analysis there was an exposure-response 293 
relationship between EPE and primary peanut sensitization when compared against high risk egg 294 
sensitized children. Fox et al. also showed that household peanut consumption during the first year 295 
of life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg allergic 296 
controls.13 In the nested cases analysis the exposure-response relationship was stronger between 297 
EPE and primary peanut sensitization (Ara h 1,2 or 3≥0.35kU/L) than between EPE and non-298 
clinically relevant peanut sensitization (peanut sIgE ≥0.35kU/L but negative results for Ara h 1,2 or 299 
3<0.35kU/L) (Figure 1). This supports the concept that EPE increases the probability of developing 300 
clinically relevant peanut sensitization which is more likely to develop into peanut allergy rather than 301 
non-specific peanut sensitization.  302 
 303 
In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin 304 
barrier (infantile eczema and FLG loss-of-function mutations) on peanut sensitization and allergy.11, 305 
12 Although in BAMSE we did not find significant interactions between EPE and FLG mutations or 306 
infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has 307 
more impact on the probability of developing peanut sensitization when compared against high risk 308 
children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole 309 
cohort analysis) than in children without these risk factors.  The BAMSE cohort is relatively non-310 
atopic, being from the general population in Sweden, which may have contributed to lower strength 311 
of associations between EPE and atopic markers. The median level of peanut protein in maternal 312 
bed-dust dust in the BAMSE cohort was 4.07µg/gram [IQR 1.58, 11.86], similar to that found in 313 
another the UK study by our group (median 4.19 IQR 0.54-24.89). 24 The level of peanut in dust was 314 
higher in a US study that measured peanut from the living room floor (median 39.1ug/g IQR 0.4-315 
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1.33). (10) It would; however, be expected that peanut levels would be higher in America due to 316 
higher levels of peanut consumption. 317 
 318 
Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this 319 
association has been cited in numerous studies.8, 28 Measures of eczema severity (extent of 320 
localisation, topical steroid use and persistent eczema) were associated with peanut sensitization on 321 
univariate analysis but were no longer associated on multivariate analysis. Eczema severity has 322 
previous been shown to be an independent risk factor for food sensitization in the EAT (Enquiring 323 
About Tolerance) study.29 The EAT study used the SCORAD eczema severity scoring system; 324 
however, this could not be performed in the BAMSE study as the evaluations at 1, 2, 4 and 8 years 325 
were based on parental questionnaires.  326 
 327 
Egg sensitization was highly associated with peanut sensitization; which has previously been shown 328 
in numerous cohort studies;11, 12, 30 it may be that egg sensitization shows a predisposition to mount 329 
allergic antibodies to other allergens as egg allergy is highly associated with the development of 330 
other food allergies, asthma and aeroallergen sensitization.31, 32 Observational studies have shown 331 
that in children with severe, early onset eczema, up to 50% are sensitized to egg;28 thus egg 332 
sensitization may be an additional marker of eczema severity. FLG loss-of-function mutations were 333 
less important than infantile eczema in predicting the development of peanut sensitization, and FLG 334 
mutations became more important if infantile eczema was not included in the regression model. 335 
Previous studies have found that children that carry a FLG mutation have an increased risk of 336 
peanut allergy even after adjusting for eczema.33 In this study eczema seemed to be the overriding 337 
factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in 338 
BAMSE (7.14%) in comparison with other population-based cohorts.26, 33, 34 Tree nut and/or soya 339 
allergy by age 8 was also associated with primary peanut sensitization at age 8 years; co-existent 340 
peanut and tree-nut allergy has been shown in numerous studies,35, 36 whereas co-existent soya and 341 
peanut allergy is reportedly low.37 342 
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 343 
Strength of the present study includes the population based design and relatively high number of 344 
study participants. Limitations of this study included the lack of diagnostic food challenges to 345 
determine peanut allergy as the BAMSE study was not originally designed to evaluate peanut 346 
allergic outcomes; however, primary peanut sensitization has been shown to be a much more 347 
accurate predictor of clinically confirmed peanut allergy than peanut specific IgE.38, 39 Certain 348 
potential confounders were not available such as parental peanut allergy or other parental food 349 
allergies, maternal peanut consumption during pregnancy and breast-feeding and infant peanut 350 
consumption. Therefore we are unable to assess whether infant peanut consumption could have 351 
protected the children against environmental exposure to peanut as has been shown in previous 352 
studies;13, 35 however, when BAMSE was recruiting participants in 1996 the number of infants eating 353 
peanut was very low. Caucasian ethnicity was based on place of parental birth rather than self-354 
reported ethnicity; however, when the BAMSE study was recruiting participants 1994-1996, most 355 
parents born in Sweden or Northern Europe would have been of Caucasian descent.40 Findings on 356 
case control analysis could not be replicated on whole cohort analysis; therefore, these findings 357 
need to be confirmed in other population based cohorts.  358 
 359 
Conclusion 360 
In summary, although EPE did not increase the risk of peanut sensitization in children who did not 361 
already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in 362 
specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later 363 
peanut sensitization. Further prospective studies are needed to confirm these findings in other 364 
populations.  365 
 366 
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Table EI: Demographics of whole studied BAMSE population with available dust and FLG 371 
genotyping (n=1878) 372 
 
Number of 
cases 
No. 
data 
points  
Percentage of cases /  
no. of available data points  
Peanut specific IgE ≥ 0.35kU/L at 4 years  103 1572 6.55% 
Peanut specific IgE ≥ 0.35kU/L at 8 years  161 1876 8.58% 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs.  
Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE 
<0.35kU/L (excluding peanut sIgE ≥0.35kU/L 
with no components or missing data) at 8 yrs 
75 1854 4.05% 
History of infantile atopic dermatitis 313 1840 17.01% 
Topical steroid use between age 1-2 years 534 1842 29.0% 
Higher extent of localisation of eczema  
(>5 areas vs. <5 areas or no eczema) 
49 1841 2.7% 
Persistent eczema at age 8 years 321 1828 17.6% 
At least one FLG mutation (R501X, 2282del or 
R2447x) 
134 1878 7.14% 
Allergic rhinitis (ISAAC definition) (age 4 years) 215 1828 11.76% 
Allergic rhinitis (ISAAC definition) (age 8 years) 288 1865 15.44% 
Egg sIgE≥ 0.35IU/ml at 4 years of age 82 1575 5.21% 
Reported allergic  reaction to any food  8 years 349 1869 18.7% 
Reported allergic  reaction to peanut by 8 years 120 1869 6.4% 
Reported allergic  reaction to milk by 8 years 53 1869 2.8% 
Reported allergic  reaction to egg by 8 years 36 1869 1.9% 
Reported allergic  reaction to fish by 8 years 12 1869 0.6% 
Reported allergic  reaction to shellfish 8 years 17 1869 0.9% 
Reported allergic  reaction to wheat by 8 years 9 1869 0.5% 
Reported allergic  reaction to soya by 8 years 21 1869 1.1% 
Reported allergic  reaction to apple by 8 years 83 1869 4.4% 
Reported allergic  reaction to peach by 8 years 44 1869 2.4% 
Reported allergic  reaction to kiwi by 8 years 92 1869 4.9% 
Reported allergic  reaction to avocado 8 years 14 1869 0.7% 
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Reported allergic  reaction to banana by 8 years 17 1869 0.9% 
Reported allergic  reaction to carrot by 8 years 53 1869 2.8% 
Reported allergic  reaction to tree nuts 8 years 105 1869 5.6% 
Male gender  973 1871 52.00% 
Caucasian ethnicity 1677 1842 91.04% 
Biological siblings 1695 1870 90.64% 
Parental atopy – (asthma/AR/eczema) 838 1858 45.10% 
Parental atopy – (asthma/AR) 605 1856 32.60% 
Maternal age (mean, SD) 
30.9 (SD 
4.49) 
1871 N/A 
Peanut protein in maternal bed-dust (µg/g): 
median [IQR] 
4.07 [1.58-
11.86] 
1878 N/A 
Exclusive breast-feeding duration (months): 
mean (SD) 
5.19 (2.43) 1838 N/A 
Total breast-feeding duration (months): mean 
(SD) 
8.73 (3.31) 1825 N/A 
  373 
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Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases 374 
versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization 375 
(≥0.35kU/L) at age 4 years and primary peanut sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) at age 8 376 
years. 377 
  
Peanut sIgE sensitized at age 4 
years (n=411) 
Peanut PAM sensitized at age 8 
years (n=195) 
OR 95% CI P value OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.23 1.06-1.43 <.01 1.29 1.04-1.61 .02 
No. of biological siblings  1.38 0.63-3.03 .42 2.50 0.77-8.16 .13 
≥1 FLG loss-of-function mutation 
(excluding non-caucasians) 
2.67 1.18-6.04 .02 3.00 0.84-10.75 .09 
History of infantile eczema 7.35 4.20-12.83 <.001 6.39 2.95-13.83 <.001 
Egg sIgE sensitization: 4 years 18.91 7.50-47.66 <.001 12.85 3.78-43.67 <.001 
*Allergic rhinitis: 4 years (ISAAC) 3.44 1.90-6.23 <.001 2.53 1.04-6.18 .04 
*Allergic rhinitis: 8 years (ISAAC) 11.44 5.68-23.07 <.001 12.97 4.54-37.05 <.001 
Exclusively breastfed (months) 0.95 0.88-1.03 .22 0.98 0.87-1.11 .77 
Breastfed (excl/partial) (months) 0.99 0.93-1.05 .74 1.01 0.93-1.11 .76 
Maternal age at baseline (in years) 0.99 0.94-1.04 .65 1.05 0.99-1.12 .12 
*Allergic rhinitis was included to assess whether false positive results for peanut sensitization were 378 
being found due to cross-reactivity with grass or tree pollens.   379 
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Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized 380 
cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE 381 
sensitization (≥0.35kU/L) at age 4 years and primary peanut sensitization (Ara h 1, 2 or 3 382 
≥0.35kU/L) at age 8 years. Non-caucasians were excluded due to inclusion of FLG mutations as a 383 
covariate.  384 
  
Peanut sIgE sensitized at age 
4 years (excluding non-
caucasians) (n=237) 
*AIC: 90.78 
Primary peanut  sensitization at 
age 8 years (excluding non-
caucasians) (n=143) 
*AIC: 49.19 
OR 95% CI P Value OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.41 1.05-1.90 .02 2.11 1.38-3.22 .001 
≥1 FLG loss-of-function mutation 3.78 0.93-15.36 .06 7.33 1.21-44.21 .03 
History of infantile eczema 2.53 0.98-6.51 .05 3.93 1.03-15.00 .05 
Egg sIgE sensitization: 4 years 28.00 5.24-149.39 <.001 39.9 1.47-1081.68 .03 
**Allergic rhinitis: 8 years (ISAAC) 12.57 4.164-37.98 <.001 28.93 3.77-221.61  <.001 
*Smaller AIC is better. **Allergic rhinitis at age 8 years was selected as it improved the fit of the 385 
model (AIC better than allergic rhinitis at age 4 years). 386 
  387 
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Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to 388 
account for repeated measures within individuals at 4 and 8 years and logistic regression for 389 
primary peanut sensitization at age 8 years in the whole BAMSE cohort (n=1878). 390 
  
GEE for peanut sIgE 
Univariate peanut sIgE 
sensitization at 4 +8 years  
Univariate primary peanut 
sensitization at age 8 years  
OR 95% CI 
P 
Value 
OR 95% CI P Value 
EPE (µg/gram ln transformed) 0.95 0.86-1.06 0.39 1.01 0.86-1.19 .89 
Gender 1.14 0.83-1.56 0.43 1.41 0.88-2.26 .15 
Full older siblings  1.08 0.63-1.85 0.77 0.86 0.40-1.81 0.68 
≥1 FLG loss-of-function mutations 1.84 1.10-3.05 0.02 1.84 0.89-3.77 0.10 
Questionaire based history of 
infantile eczema 
6.49 4.66-9.02 <.001 7.94 4.91-12.83 <.001 
Localisation of infantile eczema 
(continuous 1-10 areas/per unit) 
1.48  1.37-1.59 <.001  1.53 1.40-1.68 <.001 
Localisation of infantile eczema  
(<5 areas vs. 5+ areas) 
7.69  4.26-13.55 <.001  10.4 5.24-20.65 <.001 
Application of topical steroids for 
itchy rash (1-2 yrs) 
3.24  2.35-4.46 <.001  3.95 2.46-6.34 <.001 
Persistent eczema at age 8 years  3.87 2.76-5.44 <.001   2.85 1.69-4.81 <.001 
Egg sIgE sensitization at 4 years 13.58 8.55-21.58 <.001 11.04 6.13-19.90 <.001 
Allergic  reaction to milk by 8 years 5.68 3.12-10.34 <.001 4.24 1.84-9.77 0.001 
Allergic  reaction to egg by 8 years 26.81 13.98-51.4 <.001 16.67 7.81-35.59 <.001 
Allergic  reaction to fish by 8 years 17.25 5.41-54.96 <.001 9.18 2.39-35.32 0.001 
Allergic  reaction to shellfish 8 years 15.59 6.07-40.02 <.001 3.70 0.82-16.71 0.09 
Allergic  reaction to wheat by 8 years 9.55 2.53-36.02 0.001 8.06 1.60-40.59 0.01 
Allergic  reaction to soya by 8 years 48.75 
17.61-
134.97 
<.001 41.95 16.56-106.24 <.001 
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Allergic  reaction to apple by 8 years 12.54 8.16-19.27 <.001 5.93 3.15-11.13 <.001 
Allergic  reaction to peach by 8 years 14.37 8.15-25.34 <.001 6.49 2.88-14.61 <.001 
Allergic  reaction to kiwi by 8 years 5.95 3.80-9.31 <.001 4.25 2.20-8.20 <.001 
Allergic  reaction to avocado 8 years 12.27 4.61-32.66 <.001 4.38 0.95-20.13 0.06 
Allergic  reaction to banana 8 years 12.19 5.07-29.30 <.001 3.44 0.77-15.40 0.11 
Allergic  reaction to carrot by 8 years 17.84 10.6-30.05 <.001 7.83 3.83-16.03 <.001 
Allergic  reaction to tree nuts 8 years 21.93 
14.45-
33.28 
<.001 10.29 12.08-34.05 <.001 
Allergic rhinitis aged 4 years  2.82 1.92-4.13 <.001 2.16 1.22-3.83 0.008 
Allergic rhinitis aged 8 years  8.05 5.78-11.22 <.001 5.87 3.66-9.42 <.001 
Parental atopy (asthma and/or AR ) 1.77 1.28-2.44 <.001 1.77 1.10-2.83 0.018 
Parental atopy (asthma, AR,eczema)  1.44 1.05-1.98 0.02 1.50 0.95-2.39 0.09 
Non-caucasian ethnicity 1.58 0.97-2.57 0.07 1.09 0.49-2.43 0.79 
Exclusively breastfed in months 0.98 0.94-1.06 0.92 0.97 0.88-1.06 0.49 
Breastfed (exclusive/partial) in mo 0.99 0.94-1.03 0.57 0.97 0.91-1.04 0.43 
Maternal age at baseline (in years) 1.02 0.98-1.05 0.44 1.02 0.97-1.07 0.53 
  391 
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Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using 392 
generalised estimating equations (GEE) to account for repeated measures within individuals at 4 393 
and 8 years and logistic regression analysis for primary peanut  sensitization at age 8 years in the 394 
BAMSE cohort, Goodness of fit assessed by QIC and AIC. 395 
  
Multivariate peanut sIgE 
sensitization (excluding non-
caucasians) (1367) 
QIC:935 
Multivariate primary peanut 
sensitization  (n=1521) 
AIC:386 
OR 95% CI P Value OR 95% CI 
P 
Value 
EPE (µg/gram ln 
transformed) 
 0.94 0.80-1.11 .45 1.08 0.87-1.34 .48 
≥1 FLG loss-of-function 
mutations 
2.52 1.24-5.10 0.01  
 
ns* 
 
History of infantile eczema 2.75 1.67-4.48 <.001 4.02 2.14-7.54 <.001 
Tree nut allergic  reaction 
by age 8 years 
9.30 4.94-17.53 <.001 4.80 2.38-9.66 <.001 
Soya allergic  reaction by 
age 8 years 
18.21 4.75-69.80 <.001 2.54 
3.85-
42.07 
<.001 
Egg sIgE sensitization at 
4 years 
7.66 3.92-14.95 <.001 4.24 1.98-9.09 <.001 
Allergic rhinitis aged 8 
years (ISAAC) 
4.02 2.49-6.52 <.001 2.01 1.05-3.83 0.034 
*ns: Not significant on multivariate analysis therefore not included in final multivariate analysis.  396 
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Table V: Univariate analysis of factors associated with primary peanut  sensitization (at age 8 years) 397 
versus non primary peanut  sensitization (at age 8 years) in high risk children with preceding egg 398 
sensitization (at age 4 years) (n=134). 399 
  
Primary peanut  sensitization vs. non-peanut 
sensitized egg sensitized controls 
OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.33 1.01-1.74 <0.05 
Gender 1.90 0.95-3.80 0.07 
Full older siblings  0.61 0.17-2.13 0.44 
≥1 FLG loss-of-function mutations  
1.09 0.33-3.56 0.89 
(excluding non-caucasians) 
History of infantile eczema 2.51 1.24-5.08 0.01 
Localisation of infantile eczema (continuous 1-10 
areas/per unit) 
1.15 1.01-1.32 0.04 
Localisation of infantile eczema  
(<5 areas vs. 5+ areas) 
1.36 0.52-3.53 0.53 
Application of topical steroids for itchy rash (1-2 yrs) 1.40 0.70-2.80 0.34 
Persistent eczema at age 8 years 2.32 1.09-4.90 0.03 
Allergic  reaction to milk by 8 years 1.42 0.39-5.09 0.59 
Allergic  reaction to fish by 8 years 0.78 0.15-4.00 0.78 
Allergic  reaction to shellfish 8 years 0.30 0.06-1.58 0.16 
Allergic  reaction to wheat by 8 years 1.59 0.14-17.96 0.71 
Allergic  reaction to soya by 8 years 11.05 1.39-87.63 0.02 
Allergic  reaction to apple by 8 years 1.71 0.64-4.52 0.29 
Allergic  reaction to peach by 8 years 1.29 0.40-4.17 0.67 
Allergic  reaction to kiwi by 8 years 1.42 0.52-3.85 0.50 
Allergic  reaction to avocado 8 years 0.78 0.11-5.71 0.81 
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Allergic  reaction to banana 8 years 0.38 0.07-2.13 0.27 
Allergic  reaction to carrot by 8 years 2.36 0.71-7.85 0.16 
Allergic  reaction to tree nuts 8 years 3.43 1.54-7.62 0.002 
Allergic rhinitis aged 4 years (ISAAC) 0.87 0.38-1.96 0.73 
Allergic rhinitis aged 8 years (ISAAC) 2.65 1.26-5.56 0.01 
Parental atopy (asthma/ and /or hay-fever) 1.34 0.67-2.65 0.41 
Non-caucasian ethnicity 2.55 0.93-6.98 0.07 
Exclusively breastfed in months 0.89 0.77-1.04 0.14 
Breastfed (exclusive/partial) in months 0.99 0.89-1.09 0.76 
Maternal age at baseline (in years) 1.06 0.99-1.14 0.11 
 400 
  401 
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Legend 402 
Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut 403 
sensitization (Ara h 1,2 or 3 ≥0.35kU/L) versus children with peanut specific IgE ≥0.35kU/L but with 404 
negative results for primary peanut (Ara h 1,2 or 3<0.35kU/L). 405 
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Word count: 35382802 27 
Short Title: Environmental peanut exposure and peanut sensitization in BAMSE  28 
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Abstract 29 
Background: High household peanut consumption is associated with the development of peanut 30 
allergy, especially when peanut allergic cases are compared against atopic controls; thus 31 
environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In 32 
this study we explored the relationship between EPE and school-age peanut sensitization in a 33 
population based cohort.  34 
Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal 35 
peanut ELISA. Peanut sensitization was assessed by peanut specific IgE to peanut extract and sIgE 36 
to peanut protein component allergens molecule sensitizations (PAM) (Ara h 1, 2 or 3 ≥0.35kU/L 37 
(primary peanut sensitization)). Initial nested case control analysis was performed comparing 38 
peanut sensitized cases against high-risk controls (matched for parental atopy) (n=411) using a 39 
conditional regression analysis. This was followed by whole cohort analysis (n=1878) comparing 40 
EPE against peanut sIgE sensitization at ages 4 and 8 years using Generalized Estimating 41 
Equations and against primary peanut protein allergen molecule sensitization at age 8 years using a 42 
logistic regression model. Finally, a subgroup analysis was performed comparing the impact of EPE 43 
in peanut sensitized versus egg-sensitized peanut tolerant individuals using logistic regression 44 
analysis. Levels of EPE were compared between groups using the Mann-Whitney U test. 45 
Results: There was a significant association betweenIn the nested case control analysis, a higher 46 
level of  EPE around birth was associated with the presence of and peanut specific IgE sensitization 47 
at age 4 years (OR=1.41, 95% CI:1.05-1.90), and primary peanut protein allergen moleculePAM 48 
sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. FLG 49 
loss-of-function mutations, egg sensitization at age 4 years, infantile eczema and allergic rhinitis 50 
were significantly associated with peanut sensitization; however, there was no significant interaction 51 
with EPE.  52 
When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut 53 
sensitization; however, on subgroup analysis EPE was associated with primary peanut protein 54 
allergen moleculePAM sensitization when compared against egg-sensitized peanut-tolerant controls 55 
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with an adjusted odds ratio of 1.4456 per unit EPE (95% CI:1.0614-1.942.12). There was no 56 
significant interaction between EPE and FLG loss-of-function mutations, egg sensitization at age 4 57 
years, infantile eczema or parental atopy on peanut sensitization. 58 
 59 
Conclusions: Higher levels of environmental exposure to peanut in the first few months of life 60 
appear to EPE was associated with an increase thed probabilityrisk of developing school age 61 
peanut sensitization in atopic children specific IgE and peanut PAM sensitization at 8 years of age 62 
when comparing peanut sensitized cases against atopic controls (based on egg sensitization and 63 
parental atopy). 64 
 (egg sensitized children or children matched for parental atopy).  65 
Abstract word count: 3433 251 66 
Key words: BAMSE, egg sensitization, environmental peanut exposure, FLG mutation, infantile 67 
eczema peanut sensitization 68 
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Abbreviations 79 
AIC: Akaike information criterion 80 
Ara h: Arachis hypogaea 81 
BAMSE: Children/’Barn’ Allergy Milieu Stockholm Epidemiological project  82 
CI: confidence intervals 83 
EPE: environmental peanut exposure  84 
FLG: gene encoding the protein filaggrin 85 
GEE: Generalized Estimating Equations 86 
ISAAC: International Study of Asthma and Allergies in Childhood 87 
IQR: Interquartile range 88 
PAM: protein allergen molecule 89 
QIC: Quasi Likelihood Independence models criterion   90 
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Introduction 91 
Peanut allergy has increased,1, 2 is a leading cause of anaphylaxis in food allergy3 and has a 92 
significant impact on quality of life for the child and their family.4, 5 Most children react on first known 93 
oral exposure to peanut; thus sensitization must be occurring earlier.
6, 7
  Understanding the way 94 
children become sensitized to peanut is therefore imperative in order to prevent this condition. 95 
Observational8 and animal work9, 10 suggests that epicutaneous peanut exposure and early onset 96 
severe eczema may play an important role in peanut sensitization.  97 
 98 
Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, 99 
particularly if the skin barrier is broken through eczema or specific genetic mutations associated with 100 
skin barrier dysfunction (e.g. filaggrin (FLG) mutations or eczema). We have recently shown in the 101 
Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) 102 
cohort that FLG loss-of-function mutations and eczema severity respectively can increase the 103 
impact of early EPE on peanut sensitization and allergy.11, 12  104 
 105 
A dose response relationship has also been demonstrated between household peanut consumption 106 
(used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing 107 
peanut allergy in young children.13 They Fox et al. compared household peanut consumption in 108 
peanut allergic individuals against children who were at high risk of developing peanut allergy (due 109 
to the presence of egg allergy) but had not developed peanut allergy. Household peanut 110 
consumption was ten times higher in households with infants with peanut allergy versus children 111 
with egg allergy without peanut allergy but was only 3 times higher in non atopic controls, 112 
highlighting that household peanut consumption was more likely to be associated with peanut 113 
allergy in high risk children.13 Household peanut consumption and peanut sensitization has also 114 
been associated in other studies.14 Peanut antigen in the infant’s bed-dust and play-area-dust is 115 
highly positively correlated with household peanut consumption and stimulates basophils from 116 
peanut allergic children, thus has the potential to also sensitize individuals.15  117 
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 118 
Peanut sensitization (specific IgE≥0.35kU/L) is present in up to 10% of children and protein allergen 119 
molecule (PAM) analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown 120 
to improve the specificity and sensitivity of diagnosing peanut allergy.16, 17 In BAMSE, children with 121 
IgE reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in 122 
87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic 123 
symptoms in only 17% of cases which were also milder.18 Sweden has high levels of birch pollen 124 
sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8;18-20  thus, in this 125 
study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) and 126 
pollen cross-reactivity (IgE reactivity to Ara h 8).  127 
This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is 128 
a risk factor for the development of school-age peanut sensitization. The analysis was done in two 129 
steps for financial and logistical reasons; firstly among high risk children (with parental atopy 130 
matched to peanut sensitised cases), in a nested cases analysis and secondly among the whole 131 
studied population (a cohort analysis). Given previous findings we also wanted to ascertain the 132 
modifying effects of FLG loss-of-function mutations, infantile eczema and preceding egg 133 
sensitization.  134 
  135 
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Methods 136 
The BAMSE study is an unselected Swedish population birth cohort. The design and methodology 137 
are described elsewhere.21 In brief 4089 unselected newborn children were recruited from 1994-138 
1996 and have been evaluated for various health conditions over time. No intervention was 139 
performed. The BAMSE study obtained ethical approval for environmental sampling of dust. 140 
Demographics 141 
Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 142 
and 8 years and children were defined as ‘peanut sIgE sensitized’ if peanut specific IgE was 143 
≥0.35kU/L. Peanut protein component allergens molecules Ara h 1,2,3,8 and 9 (PAM) were 144 
assessed at 8 years (ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to 145 
peanut at age 8 years, irrespective of sensitization to birch. In addition, those children who were 146 
peanut sensitized at age 4 years but lost their sensitization at age 8 were also analyzed for these 147 
allergens. All other children with negative peanut sIgE at age 8 years were assumed to have 148 
negative component allergens to peanut. Cand children were considered to have primary be peanut 149 
PAM protein allergen molecule sensitizationed if Ara h 1, 2 or 3 was ≥0.35kU/L and not primary 150 
peanut protein allergen molecule PAM sensitizationed if Ara h 1, 2 and 3 were <0.35kU/L or peanut 151 
sIgE was <0.35kU/L at 8 years (where no sIgE peanut protein component allergens were 152 
moleculesPAM available). Twenty-four (1.3%) Cchildren with positive peanut specific IgE at 8 years 153 
of age but with no available serum for peanut protein component allergen moleculePAM analysis 154 
were excluded from this analysis. Egg sensitization was defined as egg specific IgE ≥0.35kU/L at 4 155 
years of age. Previous allergic reactions to a food including itching in the mouth, nose/eye 156 
problems, trouble breathing, vomiting or diarrhoea, eczema or nettle rash was used from parental 157 
questionnaires at age 8 years. 158 
Parental atopy was defined as a doctor’s diagnosis of asthma and prescription of asthma 159 
medication and/or a doctor’s diagnosis of hay fever in combination with furred pets- and/or pollen 160 
allergy at the time of questionnaire. This definition of parental atopy was selected rather than the 161 
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same definition with inclusion of a doctor’s diagnosis of eczema (excluding contact dermatitis); this 162 
was because the children of parents with atopy including eczema were less atopic (lower infantile 163 
eczema) and parental atopy including eczema was not associated with the outcome of interest 164 
(primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-165 
atopic. 166 
Genotyping was performed for FLG mutations common in Scandinavia by using TaqMan allelic 167 
discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-time-168 
of-flight mass spectrometry for 2282del4. Children with a FLG mutation in any of these positions 169 
were classified as having a FLG loss-of function mutation.  170 
 171 
A reported history of infantile eczema was assessed by a validated eczema questionnaire with 172 
sensitivity of 92% and specificity of 100%.22 Eczema and was defined as dry skin, itchy rashes for 2 173 
weeks or more and age specific localization (face or arms/legs extension surfaces or arms/legs 174 
flexures or wrists/ankles flexures) and/or doctor’s diagnosis of eczema after 3 months and up to 1 175 
year of age.during the first year of life. Severity of eczema was assessed from questionnaires using 176 
three different measures:  177 
1) Extent of localization of eczema (up to 10 areas) at or before their one year assessment  178 
2) Topical steroids used as treatment for an itchy rash in the last year at their two year assessment 179 
(not available at their one year assessment) 180 
3) Persistent eczema at age 8 years (using the same definition as above). 181 
 182 
Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed 183 
using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires, 184 
and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8 185 
years respectively.23 186 
 187 
Dust collection methodology 188 
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Dust samples were collected at a median of 2 months of age from the mother’s mattress. The 189 
mother’s mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control 190 
Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing 191 
filter bags were sealed in plastic bags and stored at -20ºC. Dust samples were sieved and fine dust 192 
was weighed and extracted in proportional volumes of extraction solution as previously described.24 193 
Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut 194 
protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) of the assay 195 
was defined as 100ng/ml and samples below this value were defined as 50ng/ml (LLQ/2).25 Results 196 
were converted from ng/ml into µg peanut protein/gram dust. Due to batch to batch variability of the 197 
Veratox ELISA results were batch corrected prior to being entered into the final statistical analysis.  198 
 199 
Statistical analysis 200 
Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet 201 
(Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust 202 
(µg/gram) underwent natural log transformation. Initial nested case control analysis was performed 203 
with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a 204 
2:1 control (n=274) to case (n=137) matching. Children with primary peanut protein allergen 205 
moleculePAM sensitization defined by Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were also 206 
matched against controls at age 8 years with the samematched sexfor gender and level of parental 207 
atopy with a 2:1 ratio of controls (n=130) to cases (n=65). Given that these controls were matched 208 
for the higher levels of parental atopy in the primary peanut sensitized cases these controls were 209 
deemed to be high-risk as the primary peanut sensitized cases had higher levels of parental atopy 210 
than the population overall (46.7% vs. 32.6%).Conditional logistic regression (incorporating 211 
matching) was performed for the case control analysis using robust standard error for peanut sIgE 212 
sensitization at 4 years and primary peanut sensitization at age 8 years.  213 
Subsequently analysis was performed for the relationship between early EPE and peanut 214 
sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and 215 
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FLG genotyping (n=1878). Logistic regression analysis was performed for primary peanut protein 216 
allergen moleculePAM sensitization at 8 years of age. Factors associated with peanut sIgE 217 
sensitization were assessed using Generalized Estimating Equations (GEE) with an exchangeable 218 
working correlation matrix to account for repeated measures within individuals at 4 and 8 years. 219 
Univariate followed by multivariate regression analysis was performed including EPE , FLG loss-of-220 
function mutations, infantile eczema and egg sensitization at 4 years of age plus other covariates 221 
significantly associated with peanut sensitization (P≤.05) which also improved the quality of fit of the 222 
multivariate model using the Akaike information criterion (AIC) for logistic regression and the Quasi 223 
Likelihood Independence models criterion (QIC) for GEE analyses.  224 
Where the FLG mutation covariate was entered into the statistical model, participants with missing 225 
ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct FLG 226 
loss-of-function mutations are present in different populations and the FLG loss-of-function 227 
mutations assessed in this study have only been associated with eczema in Caucasian European 228 
populations 26, 27 Peanut levels in dust (µg/g) were compared between groups using the Mann-229 
Whitney U test. Proportions between groups (e.g. infantile eczema and FLG mutations) were 230 
compared using Pearson chi-squared. Statistical significance was assessed at P<.05.  231 
  232 
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Results 233 
Details of demographics and clinical characteristics included on this study are described in Table EI.  234 
Median peanut protein [IQR] in dust was 4.07µg/gram [1.58, 11.86]. Peanut extract sIgE 235 
sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Primary 236 
pPeanut protein allergen moleculePAM sensitization at 8 years was 4.1% (n=75/1854), of which 237 
74/75 (99%) had Ara h 2 ≥0.35kU/l. We first performed a nested case control analysis, and based 238 
on positive findings for this subsequently proceeded to then analyse the whole BAMSE cohort.  239 
Nested case control analysis for peanut sIgE and primary peanut protein allergen 240 
moleculePAM sensitization  241 
We compared peanut sensitized children against children without peanut sensitization matched for 242 
gender and parental atopy as described in the statistical methods; EPE was a risk factor for both 243 
peanut extract sIgE sensitization at 4 years and primary peanut protein allergen moleculePAM 244 
sensitization at 8 years with a 23% and 29% increased probability of developing risk of peanut 245 
sensitization per natural log (ln) unit increase in EPE respectively (Table I). In children who were 246 
peanut extract sIgE sensitized but not peanut protein allergen moleculePAM sensitized to peanut 247 
protein component allergens Ara h 1, 2 and/or 3, there was only borderline significance towards an 248 
association between EPE and peanut sensitization (OR=1.20, 95% CI: 0.97-1.48).  249 
Differential relationship between EPE and primary peanut protein allergen moleculePAM 250 
sensitization and non-clinically significant peanut sensitization is displayed in Figure 1. Median 251 
peanut protein in dust was higher in peanut extract sIgE sensitized children (3.39 µg/g, IQR 1.41-252 
11.01, n=137) than non-peanut extract sIgE sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) 253 
(P<.01); and higher in primary peanut protein allergen moleculePAM sensitized children (4.64µg/g, 254 
IQR 1.58-12.77, n=65) than in control children that were not sensitized to Ara h 1,2 or 3 non-peanut 255 
protein allergen moleculePAM sensitized controls (2.24µg/g, IQR 0.88-4.74, n=130) (P<.01). 256 
On multivariate conditional logistic regression analysis, EPE was significantly associated with 257 
peanut specific IgE and primary peanut protein allergen moleculePAM sensitization with a 1.41- and 258 
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2.1-fold increased probability of developing peanut sensitization risk per unit increase EPE 259 
respectively (Table II).  260 
Infantile eczema and egg sensitization were both significantly associated with sensitization to 261 
peanut extract sIgE and protein allergen moleculePAM sensitization to peanut protein component 262 
allergens Ara h 1, 2 and/or 3.(Table II). FLG loss-of function mutations increased the risk 263 
ofprobability of developing peanut specific IgE sensitization 3.78-fold and primary peanut protein 264 
allergen moleculePAM sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated 265 
with both the probability of developing peanut specific IgE sensitization at age 4 years and primary 266 
peanut protein allergen moleculePAM sensitization at age 8 years in the multivariate analysis. The 267 
number of biological siblings, duration of exclusive and total breastfeeding and maternal age at 268 
baseline were not risk factorsassociated with  for peanut sensitization. There was no significant 269 
interaction between EPE and either infantile eczema, egg sensitization or FLG loss-of-function 270 
mutations on primary peanut protein allergen moleculePAM sensitization (data not shown).  271 
 272 
Whole cohort analysis for peanut extract sIgE sensitization and primary peanut 273 
sensitizationprotein allergen moleculePAM sensitization  274 
In a second step following positive findings obtained on case control analysis, we assessedanalysis 275 
was performed for the relationship between early EPE and peanut sensitization in all children from 276 
the BAMSE cohort with available postnatal maternal bed-dust and FLG genotyping (n=1878). On 277 
both univariate (Table III) and multivariate analysis (Table IV) infantile eczema, egg sensitization at 278 
age 4 years, tree nut and soya allergy at age 8 years, FLG loss-of function mutation and allergic 279 
rhinitis at age 8 years were associated with the probability of peanut extract sIgE sensitization at 280 
age 4 and 8 years. For primary peanut protein allergen moleculePAM sensitization at age 8 281 
significant associations were also seen on univariate (Table III) and multivariate analysis (Table IV) 282 
for infantile eczema, egg sensitization, tree nut and soya allergy at age 8 years and allergic rhinitis 283 
at age 8 years. Although measures of eczema severity several other food allergies at age 8 years 284 
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were significantly association with peanut sensitization on univariate analysis, these variables were 285 
no longer significantly associated on multivariate analysis. However, EPE was not longer associated 286 
with peanut sIgE sensitization or primary peanut protein allergen molecule sensitization. There was 287 
no interaction between EPE and FLG mutations, infantile eczema, egg sensitization, allergic  288 
reaction to tree nut or soya by age 8 years, or parental atopy on peanut sensitization.  289 
 290 
Subgroup analysis of primary peanut protein allergen moleculePAM sensitization against egg 291 
sensitized non peanut allergic individuals  292 
On subgroup analysis we compared primary peanut protein allergen moleculePAM sensitized 293 
children (n=75) against children who were sensitized to egg (sIgE≥0.35kU/L at age 4 years) but did 294 
not go on to develop have primary peanut protein allergen moleculePAM sensitization at age 8 295 
years (n=59). EPE increased the probability was a risk factor forof primary peanut protein allergen 296 
moleculePAM sensitization on both univariate (OR=1.33 95% CI:1.01-1.74, P<.05, n=134) (Table V) 297 
and multivariate analysis (OR=1.4456, 95% CI:1.0614-1.942.12, P0<.018, n=1332, AIC: 167331) 298 
adjusting for allergic rhinitis at age 8 years and infantile eczema and allergic  reaction to soya by 299 
age 8 years. Peanut levels in household dust were also significantly higher in primary peanut 300 
protein allergen moleculePAM sensitized children (median 4.79µg/g, IQR 1.63-12.00) versus egg 301 
sensitized, non-primary peanut protein allergen moleculePAM sensitized children (median 2.35µg/g, 302 
IQR 1.23-6.15) (P=.03).  303 
We assessed the impact of EPE on peanut sensitization when using other high-risk groups of 304 
children who were not did not become peanut sensitized at age 8 years (FLG mutations, infantile 305 
eczema, soya allergy and , parental atopy) and there was no significant association.   306 
  307 
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Discussion 308 
In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE 309 
(quantified using peanut protein levels from maternal mattress-dust postnatally) and primary peanut 310 
protein allergen moleculePAM sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) among high risk children (in 311 
a nested cases analysis). When all children in the whole studied population were assessed, there 312 
was no association between EPE and peanut sensitization; however, on subgroup analysis there 313 
was an exposure-response relationship between EPE and primary peanut protein allergen 314 
moleculePAM sensitization when compared against high risk egg sensitized children. 315 
 316 
This supports the findings by Fox et al. also showed that where household peanut consumption 317 
during the first year of life (as an indirect marker of EPE) was higher in peanut allergic cases than in 318 
egg allergic controls.13 In the nested cases analysis tThe exposure-response relationship between 319 
EPE and PS (when compared against atopic controls) was stronger between EPE and primary 320 
peanut protein allergen moleculeCRD sensitization (Ara h 1,2 or 3≥0.35kU/L) than between EPE 321 
and non-clinically relevant peanut sensitization (peanut sIgE ≥0.35kU/L but negative results for Ara 322 
h 1,2 or 3<0.35kU/L) (Figure 1). This supports the concept that EPE increases the probability of 323 
developing clinically relevant peanut sensitization which is more likely to develop into peanut allergy 324 
rather than non-specific peanut sensitization.  325 
 326 
The association between household peanut consumption and peanut sensitization was also found 327 
in a study by Garcia-Boyano et al. 14 and  supports the concept that EPE increases the risk of 328 
clinically relevant peanut sensitization.  329 
 330 
In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin 331 
barrier (infantile eczema and FLG loss-of-function mutations) on peanut sensitization and allergy.11, 332 
12 Although in BAMSE we did not find significant interactions between EPE and FLG mutations or 333 
infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has 334 
more impact on the probability of developing peanut sensitization when compared against high risk 335 
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children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole 336 
cohort analysis) in children with certain risk factors for the development of peanut sensitization 337 
(such as parental atopy or egg sensitization) than in children without these risk factors. The BAMSE 338 
cohort is relatively non-atopic, being from the general population in Sweden, which may have 339 
contributed to lower strength of associations between EPE and atopic markers. The median level of 340 
peanut protein in maternal bed-dust dust in the BAMSE cohort was 4.07µg/gram [IQR 1.58, 11.86], 341 
similar to that found in another the UK study by our group (median 4.19 IQR 0.54-24.89). 24 The 342 
level of peanut in dust was higher in a US study that measured peanut from the living room floor 343 
(median 39.1ug/g IQR 0.4-1.33). (10) It would; however, be expected that peanut levels would be 344 
higher in America due to higher levels of peanut consumption. 345 
 346 
Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this 347 
association has been cited in numerous studies.8, 28 FLG loss-of-function mutations were less 348 
important than infantile eczema in predicting the development of peanut sensitization, and FLG 349 
mutations became more important if infantile eczema was not included in the regression model. 350 
Previous studies have found that children that carry a FLG mutation have an increased risk of 351 
peanut allergy even after adjusting for eczema.29 In this study eczema seemed to be the overriding 352 
factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in 353 
BAMSE (7.14%) in comparison with other population-based cohorts.26, 29 Measures of eczema 354 
severity (extent of localisation, topical steroid use and persistent eczema) were associated with 355 
peanut sensitization on univariate analysis but were no longer associated on multivariate analysis. 356 
Eczema severity has previous been shown to be an independent risk factor for food sensitization in 357 
the EAT (Enquiring About Tolerance) study.30 The EAT study used the SCORAD eczema severity 358 
scoring system; however, this could not be performed in the BAMSE study as the evaluations at 1, 359 
2, 4 and 8 years were based on parental questionnaires.  360 
 361 
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Egg sensitization was highly associated with peanut sensitization; which has previously been shown 362 
in numerous cohort studies;11, 12, 31 it may be that egg sensitization shows a predisposition to mount 363 
allergic antibodies to other allergens as egg allergy is highly associated with the development of 364 
other food allergies, asthma and aeroallergen sensitization.32, 33 Observational studies have shown 365 
that in children with severe, early onset eczema, up to 50% are sensitized to egg;28 thus egg 366 
sensitization may be an additional marker of eczema severity. FLG loss-of-function mutations were 367 
less important than infantile eczema in predicting the development of peanut sensitization, and FLG 368 
mutations became more important if infantile eczema was not included in the regression model. 369 
Previous studies have found that children that carry a FLG mutation have an increased risk of 370 
peanut allergy even after adjusting for eczema.29 In this study eczema seemed to be the overriding 371 
factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in 372 
BAMSE (7.14%) in comparison with other population-based cohorts.26, 29, 34 Tree nut and/or soya 373 
allergy by age 8 was also associated with primary peanut sensitization at age 8 years; co-existent 374 
peanut and tree-nut allergy has been shown in numerous studies,35, 36 whereas co-existent soya and 375 
peanut allergy is reportedly low.37 376 
 377 
Strength of the present study includes the population based design and relatively high number of 378 
study participants. Limitations of this study included the lack of diagnostic food challenges to 379 
determine peanut allergy as the BAMSE study was not originally designed to evaluate peanut 380 
allergic outcomes; however, primary peanut protein allergen moleculePAM sensitization has been 381 
shown to be a much more accurate predictor of clinically confirmed peanut allergy than peanut 382 
specific IgE.38, 39 Certain potential confounders were not available such as parental peanut allergy or 383 
other parental food allergies, maternal peanut consumption during pregnancy and breast-feeding 384 
and infant peanut consumption. Therefore we are unable to assess whether infant peanut 385 
consumption could have protected the children against environmental exposure to peanut 386 
sensitization as has been shown in previous studies;13, 35 however, when BAMSE was recruiting 387 
participants in 1996 the number of infants eating peanut was very low. Caucasian ethnicity was 388 
defined based on place of parental birth rather than self-reported ethnicity; however, when the 389 
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BAMSE study was recruiting participants 1994-1996, most parents born in Sweden or Northern 390 
Europe would have been of Caucasian descent. as being born in Sweden as between 1994-1996 391 
(when the BAMSE cohort commenced), most participants born in Sweden would have been of 392 
Northern European descent. In addition participants from Finland, Greece or Eastern Europe who 393 
were not born in Sweden were also defined as Caucasian.40 Findings on case control analysis could 394 
not be replicated on whole cohort analysis, therefore these findings need to be confirmed in other 395 
population based cohorts. Strength of the present study includes the population based design and 396 
relatively high number of study participants.  397 
 398 
Conclusion 399 
In summary, although EPE did not increase the risk of peanut sensitization in children who did not 400 
already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in 401 
specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later 402 
peanut sensitization. Further prospective studies are needed to confirm these findings in other 403 
populations.  404 
 405 
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Table EI: Demographics of whole studied BAMSE population with available dust and FLG 504 
genotyping (n=1878) 505 
 
Number of 
cases 
No. 
data 
points  
Percentage of cases /  
no. of available data points  
Peanut specific IgE ≥ 0.35kU/L at 4 years  103 1572 6.55% 
Peanut specific IgE ≥ 0.35kU/L at 8 years  161 1876 8.58% 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs.  
Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE 
<0.35kU/L (excluding peanut sIgE ≥0.35kU/L 
with no components or missing data) at 8 yrs 
75 1854 4.05% 
History of infantile atopic dermatitis 313 1840 17.01% 
Topical steroid use between age 1-2 years 534 1842 29.0% 
Higher extent of localisation of eczema  
(>5 areas vs. <5 areas or no eczema) 
49 1841 2.7% 
Persistent eczema at age 8 years 321 1828 17.6% 
At least one FLG mutation (R501X, 2282del or 
R2447x) 
134 1878 7.14% 
Allergic rhinitis (ISAAC definition) (age 4 years) 215 1828 11.76% 
Allergic rhinitis (ISAAC definition) (age 8 years) 288 1865 15.44% 
Egg sIgE≥ 0.35IU/ml at 4 years of age 82 1575 5.21% 
Reported allergic  reaction to any food  8 years 349 1869 18.7% 
Reported allergic  reaction to peanut by 8 years 120 1869 6.4% 
Reported allergic  reaction to milk by 8 years 53 1869 2.8% 
Reported allergic  reaction to egg by 8 years 36 1869 1.9% 
Reported allergic  reaction to fish by 8 years 12 1869 0.6% 
Reported allergic  reaction to shellfish 8 years 17 1869 0.9% 
Reported allergic  reaction to wheat by 8 years 9 1869 0.5% 
Reported allergic  reaction to soya by 8 years 21 1869 1.1% 
Reported allergic  reaction to apple by 8 years 83 1869 4.4% 
Reported allergic  reaction to peach by 8 years 44 1869 2.4% 
Reported allergic  reaction to kiwi by 8 years 92 1869 4.9% 
Reported allergic  reaction to avocado 8 years 14 1869 0.7% 
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Reported allergic  reaction to banana by 8 years 17 1869 0.9% 
Reported allergic  reaction to carrot by 8 years 53 1869 2.8% 
Reported allergic  reaction to tree nuts 8 years 105 1869 5.6% 
Male gender  973 1871 52.00% 
Caucasian ethnicity 1677 1842 91.04% 
Biological siblings 1695 1870 90.64% 
Parental atopy – (asthma/AR/eczemaAD) 838 1858 45.10% 
Parental atopy – (asthma/AR) 605 1856 32.60% 
Maternal age (mean, SD) 
30.9 (SD 
4.49) 
1871 N/A 
Peanut protein in maternal bed-dust (µg/g): 
median [IQR] 
4.07 [1.58-
11.86] 
1878 N/A 
Exclusive breast-feeding duration (months): 
mean (SD) 
5.19 (2.43) 1838 N/A 
Total breast-feeding duration (months): mean 
(SD) 
8.73 (3.31) 1825 N/A 
 506 
  507 
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Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases 508 
versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization 509 
(≥0.35kU/L) at age 4 years and primary peanut protein allergen moleculePAM sensitization (Ara h 1, 510 
2 or 3 ≥0.35kU/L) at age 8 years. 511 
  
Peanut sIgE sensitized at age 4 
years (n=411) 
Peanut PAM sensitized at age 8 
years (n=195) 
OR 95% CI P value OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.23 1.06-1.43 <.01 1.29 1.04-1.61 .02 
No. of biological siblings  1.38 0.63-3.03 .42 2.50 0.77-8.16 .13 
≥1 FLG loss-of-function mutation 
(excluding non-caucasians) 
2.67 1.18-6.04 .02 3.00 0.84-10.75 .09 
History of infantile eczema 7.35 4.20-12.83 <.001 6.39 2.95-13.83 <.001 
Egg sIgE sensitization: 4 years 18.91 7.50-47.66 <.001 12.85 3.78-43.67 <.001 
*Allergic rhinitis: 4 years (ISAAC) 3.44 1.90-6.23 <.001 2.53 1.04-6.18 .04 
*Allergic rhinitis: 8 years (ISAAC) 11.44 5.68-23.07 <.001 12.97 4.54-37.05 <.001 
Exclusively breastfed (months) 0.95 0.88-1.03 .22 0.98 0.87-1.11 .77 
Breastfed (excl/partial) (months) 0.99 0.93-1.05 .74 1.01 0.93-1.11 .76 
Maternal age at baseline (in years) 0.99 0.94-1.04 .65 1.05 0.99-1.12 .12 
*Allergic rhinitis was included to assess whether false positive results for peanut sensitization were 512 
being found due to cross-reactivity with grass or tree pollens.   513 
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Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized 514 
cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE 515 
sensitization (≥0.35kU/L) at age 4 years and primary peanut protein allergen moleculePAM 516 
sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) at age 8 years. Non-caucasians were excluded due to 517 
inclusion of FLG mutations as a covariate.  518 
  
Peanut sIgE sensitized at age 
4 years (excluding non-
caucasians) (n=237) 
*AIC: 90.78 
Primary pPeanut PAM 
sensitizationed at age 8 years 
(excluding non-caucasians) 
(n=143) 
*AIC: 49.19 
OR 95% CI P Value OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.41 1.05-1.90 .02 2.11 1.38-3.22 .001 
≥1 FLG loss-of-function mutation 3.78 0.93-15.36 .06 7.33 1.21-44.21 .03 
History of infantile eczema 2.53 0.98-6.51 .05 3.93 1.03-15.00 .05 
Egg sIgE sensitization: 4 years 28.00 5.24-149.39 <.001 39.9 1.47-1081.68 .03 
**Allergic rhinitis: 8 years (ISAAC) 12.57 4.164-37.98 <.001 28.93 3.77-221.61  <.001 
*Smaller AIC is better. **Allergic rhinitis at age 8 years was selected as it improved the fit of the 519 
model (AIC better than allergic rhinitis at age 4 years). 520 
  521 
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Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to 522 
account for repeated measures within individuals at 4 and 8 years and logistic regression for 523 
primary peanut PAM sensitization at age 8 years in the whole BAMSE cohort (n=1878). 524 
  
GEE for peanut sIgE 
Univariate peanut sIgE 
sensitisation at 4 +8 years  
Univariate primary peanut 
sensitisation at age 8 years  
OR 95% CI 
P 
Value 
OR 95% CI P Value 
EPE (µg/gram ln transformed) 0.95 0.86-1.06 0.39 1.01 0.86-1.19 .89 
Gender 1.14 0.83-1.56 0.43 1.41 0.88-2.26 .15 
Full older siblings  1.08 0.63-1.85 0.77 0.86 0.40-1.81 0.68 
≥1 FLG loss-of-function mutations 1.84 1.10-3.05 0.0219 1.84 0.89-3.77 0.10 
Questionaire based history of 
infantile eczema 
6.49 4.66-9.02 <.001 7.94 4.91-12.83 <.001 
Localisation of infantile eczema 
(continuous 1-10 areas/per unit) 
1.48  1.37-1.59 <.001  1.53 1.40-1.68 <.001 
Localisation of infantile eczema  
(<5 areas vs. 5+ areas) 
7.69  4.26-13.55 <.001  10.4 5.24-20.65 <.001 
Application of topical steroids for 
itchy rash (1-2 yrs) 
3.24  2.35-4.46 <.001  3.95 2.46-6.34 <.001 
Persistent eczema at age 8 years  3.87 2.76-5.44 <.001   2.85 1.69-4.81 <.001 
Egg sIgE sensitisation at 4 years 13.58 8.55-21.58 <.001 11.04 6.13-19.90 <.001 
Allergic  reaction to milk by 8 years 5.68 3.12-10.34 <.001 4.24 1.84-9.77 0.001 
Allergic  reaction to egg by 8 years 26.81 13.98-51.4 <.001 16.67 7.81-35.59 <.001 
Allergic  reaction to fish by 8 years 17.25 5.41-54.96 <.001 9.18 2.39-35.32 0.001 
Allergic  reaction to shellfish 8 years 15.59 6.07-40.02 <.001 3.70 0.82-16.71 0.09 
Allergic  reaction to wheat by 8 years 9.55 2.53-36.02 0.001 8.06 1.60-40.59 0.01 
Allergic  reaction to soya by 8 years 48.75 
17.61-
134.97 
<.001 41.95 16.56-106.24 <.001 
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Allergic  reaction to apple by 8 years 12.54 8.16-19.27 <.001 5.93 3.15-11.13 <.001 
Allergic  reaction to peach by 8 years 14.37 8.15-25.34 <.001 6.49 2.88-14.61 <.001 
Allergic  reaction to kiwi by 8 years 5.95 3.80-9.31 <.001 4.25 2.20-8.20 <.001 
Allergic  reaction to avocado 8 years 12.27 4.61-32.66 <.001 4.38 0.95-20.13 0.06 
Allergic  reaction to banana 8 years 12.19 5.07-29.30 <.001 3.44 0.77-15.40 0.11 
Allergic  reaction to carrot by 8 years 17.84 10.6-30.05 <.001 7.83 3.83-16.03 <.001 
Allergic  reaction to tree nuts 8 years 21.93 
14.45-
33.28 
<.001 10.29 12.08-34.05 <.001 
Allergic rhinitis aged 4 years  2.82 1.92-4.13 <.001 2.16 1.22-3.83 0.008 
Allergic rhinitis aged 8 years  8.05 5.78-11.22 <.001 5.87 3.66-9.42 <.001 
Parental atopy (asthma and/or AR ) 1.77 1.28-2.44 <.001 1.77 1.10-2.83 0.018 
Parental atopy (asthma, AR,eczema)  1.44 1.05-1.98 0.02 1.50 0.95-2.39 0.09 
Non-caucasian ethnicity 1.58 0.97-2.57 0.07 1.09 0.49-2.43 0.79 
Exclusively breastfed in months 0.98 0.94-1.06 0.92 0.97 0.88-1.06 0.49 
Breastfed (exclusive/partial) in mo 0.99 0.94-1.03 0.57 0.97 0.91-1.04 0.43 
Maternal age at baseline (in years) 1.02 0.98-1.05 0.44 1.02 0.97-1.07 0.53 
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Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using 526 
generalised estimating equations (GEE) to account for repeated measures within individuals at 4 527 
and 8 years and logistic regression analysis for primary peanut PAM sensitization at age 8 years in 528 
the BAMSE cohort.. excluding non-caucasians. Goodness of fit assessed by QIC and AIC. 529 
  
Multivariate peanut sIgE 
sensitization (excluding non-
caucasians) (136788) 
QIC:935.41094 
Multivariate primary peanut 
PAM sensitization (excluding 
non-caucasians) (n=1521375) 
AIC:386767 
OR 95% CI P Value OR 95% CI 
P 
Value 
EPE (µg/gram ln 
transformed) 
 0.948 0.8084-1.113 .4575 1.088 
0.878-
1.342 
.48 
≥1 FLG loss-of-function 
mutations 
2.5237 1.242-5.104.60 0.01 1.82 
0.72-4.57 
ns 
.20 
History of infantile eczema 2.753.81 
1.672.44-
4.485.94 
<.001 4.025.51 
2.14-
7.543.03-
10.03 
<.001 
Tree nut allergic  reaction 
by age 8 years 
9.30 4.94-17.53 <.001 4.80 2.38-9.66 <.001 
Soya allergic  reaction by 
age 8 years 
18.21 4.75-69.80 <.001 2.54 
3.85-
42.07 
<.001 
Egg sIgE sensitization at 
4 years 
7.668.12 
3.924.35-
14.955.15 
<.001 4.246.61 
1.98-
9.093.16-
13.80 
<.001 
Allergic rhinitis aged 8 
years (ISAAC) 
4.025.57 
2.493.57-
6.528.71 
<.001 2.013.05 
1.0565-
3.835.63 
0<.034
01 
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ns: Not significant on multivariate analysis therefore not included in final multivariate analysis.  531 
Table V: Univariate analysis of factors associated with primary peanut PAM sensitization (at age 8 532 
years) versus non primary peanut PAM sensitization (at age 8 years) in high risk children with 533 
preceding egg sensitization (at age 4 years) (n=134). 534 
  
Primary peanut PAM sensitization vs. non-
peanut sensitized egg sensitized controls 
OR 95% CI P Value 
EPE (µg/gram ln transformed) 1.33 1.01-1.74 <0.05 
Gender 1.90 0.95-3.80 0.07 
Full older siblings  0.61 0.17-2.13 0.44 
≥1 FLG loss-of-function mutations  
1.09 0.33-3.56 0.89 
(excluding non- caucasians) 
History of infantile eczema 2.51 1.24-5.08 0.01 
Localisation of infantile eczema (continuous 1-10 
areas/per unit) 
1.15 1.01-1.32 0.04 
Localisation of infantile eczema  
(<5 areas vs. 5+ areas) 
1.36 0.52-3.53 0.53 
Application of topical steroids for itchy rash (1-2 yrs) 1.40 0.70-2.80 0.34 
Persistent eczema at age 8 years 2.32 1.09-4.90 0.03 
Allergic  reaction to milk by 8 years 1.42 0.39-5.09 0.59 
Allergic  reaction to fish by 8 years 0.78 0.15-4.00 0.78 
Allergic  reaction to shellfish 8 years 0.30 0.06-1.58 0.16 
Allergic  reaction to wheat by 8 years 1.59 0.14-17.96 0.71 
Allergic  reaction to soya by 8 years 11.05 1.39-87.63 0.02 
Allergic  reaction to apple by 8 years 1.71 0.64-4.52 0.29 
Allergic  reaction to peach by 8 years 1.29 0.40-4.17 0.67 
Allergic  reaction to kiwi by 8 years 1.42 0.52-3.85 0.50 
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Allergic  reaction to avocado 8 years 0.78 0.11-5.71 0.81 
Allergic  reaction to banana 8 years 0.38 0.07-2.13 0.27 
Allergic  reaction to carrot by 8 years 2.36 0.71-7.85 0.16 
Allergic  reaction to tree nuts 8 years 3.43 1.54-7.62 0.002 
Allergic rhinitis aged 4 years (ISAAC) 0.87 0.38-1.96 0.73 
Allergic rhinitis aged 8 years (ISAAC) 2.65 1.26-5.56 0.01 
Parental atopy (asthma/ and /or hay-fever) 1.34 0.67-2.65 0.41 
Non-caucasian ethnicity 2.55 0.93-6.98 0.07 
Exclusively breastfed in months 0.89 0.77-1.04 0.14 
Breastfed (exclusive/partial) in months 0.99 0.89-1.09 0.76 
Maternal age at baseline (in years) 1.06 0.99-1.14 0.11 
 535 
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Legend 537 
Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut PAM 538 
sensitization (Ara h 1,2 or 3 ≥0.35kU/L) versus children with peanut specific IgE ≥0.35kU/L but with 539 
negative results for primary peanut PAM (Ara h 1,2 or 3<0.35kU/L). 540 
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